##### Table of Contents





UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549





Form 10-Q/A

Amendment No. 1







|x | QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
|- | ---------------------------------------------------------------------------------------

For the quarterly period ended March 31, 2009

Commission File Number: 001-33151





HANSEN MEDICAL,
INC.

(Exact name of registrant as specified in its charter)







|                         |  |                                     
|------------------------ |  | ------------------------------------
|Delaware                 |  | 14-1850535                          
|(State of Incorporation) |  | (I.R.S. Employer Identification No.)

800 East Middlefield Road, Mountain View, CA 94043

(Address of Principal Executive Offices)

(650) 404-5800

(Registrants telephone number, including area code)





Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the
Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90
days.    Yes  x    No   ̈

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive
Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such
files).    Yes   ̈    No   ̈

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer or a smaller
reporting company. See definition of large accelerated filer, accelerated filer and smaller reporting company in Rule 12b-2 of the Exchange Act.



|                        |  |                                                  |  |                           |  |  
|----------------------- |  | ------------------------------------------------ |  | ------------------------- |  | -
|Large accelerated filer |  |  ̈                                                |  | Accelerated filer         |  | x
|                        |  |                                                  | 
|Non-accelerated filer   |  |  ̈  (Do not check if a smaller reporting company) |  | Smaller reporting company |  |  ̈

Indicate by check mark whether the registrant is a shell company (as defined in Rule
12b-2 of the Exchange Act).    Yes   ̈    No  x

The number of shares outstanding of the registrants common stock as of April 30, 2009 was 37,269,051.









---

##### Table of Contents

EXPLANATORY NOTE

Hansen Medical, Inc. (the Company) previously announced its intention to restate its consolidated financial statements for the
years ended December 31, 2007 and 2008, for each of the quarters of the year ended December 31, 2008, and for the first two quarters of the year ending December 31, 2009 as a result of the improper recognition of revenue with regard
to sales of Sensei Robotic Catheter Systems. Through June 30, 2009, the Company shipped 68 systems based on valid customer purchase orders for which revenue previously had been recognized. As of November 10, 2009, the Company had received full
payment for all but one of these systems.

The Company is filing this Quarterly Report on Form 10-Q/A (the
Form 10-Q/A) for the quarter ended March 31, 2009 to reflect the restatement of its condensed consolidated financial statements, the notes thereto and related disclosures for the quarter ended March 31, 2009. The Company
is concurrently filing an amendment to the Companys annual report on Form 10-K for the year ended December 31, 2008, in order to restate its consolidated financial statements as of December 31, 2007 and 2008, and filing
amendments to its quarterly reports on Form 10-Q for the quarters ended March 31, 2008, June 30, 2008, September 30, 2008 and June 30, 2009 to restate its condensed consolidated financial statements for such periods.

In August 2009, the Company received an anonymous whistleblower report alleging a single irregularity that
resulted in improper revenue recognition in the quarter ended December 31, 2008. The Companys audit committee, with the assistance of independent outside counsel, undertook an investigation into the allegation and a review of the
Companys historical revenue recognition practices. The audit committees investigation determined that information was withheld from the Companys accounting department and independent auditors, documentation related to certain
revenue transactions was falsified, and there was not an effective control environment in the Companys sales, clinical and field service departments. This led to incomplete information regarding temporary installations, unfulfilled training
obligations, the inability of distributors to independently install systems and train end users, and undisclosed side arrangements. As a result, there were instances where revenue was recognized prior to the completion of all of the elements
required for revenue recognition under the Companys revenue recognition policy. All of the irregularities that were identified during the investigation occurred outside of the accounting department. The Company is implementing revised controls
and procedures designed to prevent a recurrence of the improper recognition of revenue. For more information on these matters, please refer to Note 3 of the Notes to the Condensed Consolidated Financial Statements, Item 2,
Managements Discussion and Analysis of Financial Condition and Results of Operations and Item 4, Controls and Procedures.

This Form 10-Q/A has not been updated except as required to reflect the effects of the restatement. This amendment and restatement includes changes to Part I, Items 1, 2, 3 and 4. No other
items included in the original Form 10-Q have been amended, and such items remain in effect as of the filing date of the original Form 10-Q. Additionally, this Form 10-Q/A does not purport to provide an update or a discussion of any
other developments at the Company subsequent to the original filing. Accordingly, this Form 10-Q/A should be read in conjunction with our periodic filings made with the Securities and Exchange Commission.



---

##### Table of Contents

INDEX



|                               |  |                                                                                                                           |  |   
|------------------------------ |  | ------------------------------------------------------------------------------------------------------------------------- |  | --
|PART I - FINANCIAL INFORMATION
|                               |  |                                                                                                                          
|Item 1.                        |  | Condensed Consolidated Financial Statements (unaudited)                                                                   |  |   
|                               |  |                                                                                                                          
|                               |  | Condensed Consolidated Balance Sheets as of March 31, 2009 (restated) and December 31, 2008
(restated)                    |  | 1 
|                               |  |                                                                                                                          
|                               |  | Condensed Consolidated Statements of Operations for the three months ended March 31, 2009 (restated) and 2008
 (restated) |  | 2 
|                               |  |                                                                                                                          
|                               |  | Condensed Consolidated Statements of Cash Flows for the three months ended March 31, 2009 (restated) and 2008
 (restated) |  | 3 
|                               |  |                                                                                                                          
|                               |  | Notes to Condensed Consolidated Financial Statements (restated)                                                           |  | 4 
|                               |  |                                                                                                                          
|Item 2.                        |  | Managements Discussion and Analysis of Financial Condition and Results of Operations (restated)                          |  | 16
|                               |  |                                                                                                                          
|Item 3.                        |  | Quantitative and Qualitative Disclosures About Market Risk (restated)                                                     |  | 23
|                               |  |                                                                                                                          
|Item 4.                        |  | Controls and Procedures (restated)                                                                                        |  | 24
|                               |  |                                                                                                                          
|Item 4T.                       |  | Controls and Procedures                                                                                                   |  | 26
|                               | 
|PART II - OTHER INFORMATION    |  |                                                                                                                          
|                               |  |                                                                                                                          
|Item 1.                        |  | Legal Proceedings                                                                                                         |  | 26
|                               |  |                                                                                                                          
|Item 1A.                       |  | Risk Factors                                                                                                              |  | 26
|                               |  |                                                                                                                          
|Item 2.                        |  | Unregistered Sales of Equity Securities and Use of Proceeds                                                               |  | 53
|                               |  |                                                                                                                          
|Item 3.                        |  | Defaults Upon Senior Securities                                                                                           |  | 53
|                               |  |                                                                                                                          
|Item 4.                        |  | Submission of Matters to a Vote of Security Holders                                                                       |  | 53
|                               |  |                                                                                                                          
|Item 5.                        |  | Other Information                                                                                                         |  | 53
|                               |  |                                                                                                                          
|Item 6.                        |  | Exhibits                                                                                                                  |  | 54
|                               | 
|Signatures                     |  | 55                                                                                                                       



---

##### Table of Contents

PART I. FINANCIAL INFORMATION



|ITEM 1. | FINANCIAL STATEMENTS (Restated)
|------- | -------------------------------

HANSEN MEDICAL, INC.

Condensed Consolidated Balance Sheets

(Unaudited)

(In thousands, except share and per share data)



|                                                                                                                                                                             |  |               |          |   |                  |   |          |  
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------- |  | ------------- | -------- | - | ---------------- | - | -------- | -
|                                                                                                                                                                             |  | March 31,2009 |          |   | December 31,2008 |  
|                                                                                                                                                                             |  | As Restated   |          |   | As Restated      |  
|ASSETS                                                                                                                                                                       |  |               |          |   |                  |   |          |  
|Current assets:                                                                                                                                                              |  |               |          |   |                  |   |          |  
|Cash and cash equivalents                                                                                                                                                    |  | $             | 15,671   |   |                  | $ | 17,377   |  
|Short-term investments                                                                                                                                                       |  |               | 13,584   |   |                  |   | 17,846   |  
|Accounts receivable, net                                                                                                                                                     |  |               | 6,749    |   |                  |   | 9,506    |  
|Inventories                                                                                                                                                                  |  |               | 5,733    |   |                  |   | 6,426    |  
|Deferred cost of goods sold                                                                                                                                                  |  |               | 2,105    |   |                  |   | 2,364    |  
|Prepaids and other current assets                                                                                                                                            |  |               | 1,894    |   |                  |   | 2,136    |  
|                                                                                                                                                                             |  |               |          |   |                  |   |          |  
|Total current assets                                                                                                                                                         |  |               | 45,736   |   |                  |   | 55,655   |  
|                                                                                                                                                                             |  |              
|Property and equipment, net                                                                                                                                                  |  |               | 17,310   |   |                  |   | 18,195   |  
|Restricted cash                                                                                                                                                              |  |               | 110      |   |                  |   | 110      |  
|Other assets                                                                                                                                                                 |  |               | 179      |   |                  |   | 174      |  
|                                                                                                                                                                             |  |               |          |   |                  |   |          |  
|Total assets                                                                                                                                                                 |  | $             | 63,335   |   |                  | $ | 74,134   |  
|                                                                                                                                                                             |  |               |          |   |                  |   |          |  
|LIABILITIES AND STOCKHOLDERS EQUITY                                                                                                                                         |  |               |          |   |                  |   |          |  
|Current liabilities:                                                                                                                                                         |  |               |          |   |                  |   |          |  
|Accounts payable                                                                                                                                                             |  | $             | 3,574    |   |                  | $ | 3,089    |  
|Accrued liabilities                                                                                                                                                          |  |               | 6,570    |   |                  |   | 5,634    |  
|Current portion of deferred revenue                                                                                                                                          |  |               | 7,828    |   |                  |   | 8,794    |  
|Current portion of long-term debt                                                                                                                                            |  |               | 3,290    |   |                  |   | 2,451    |  
|                                                                                                                                                                             |  |               |          |   |                  |   |          |  
|Total current liabilities                                                                                                                                                    |  |               | 21,262   |   |                  |   | 19,968   |  
|                                                                                                                                                                             |  |              
|Deferred revenue, net of current portion                                                                                                                                     |  |               | 153      |   |                  |   | 189      |  
|Long-term debt, net of current portion                                                                                                                                       |  |               | 9,186    |   |                  |   | 10,025   |  
|Other long-term liabilities                                                                                                                                                  |  |               | 1,104    |   |                  |   | 1,109    |  
|                                                                                                                                                                             |  |               |          |   |                  |   |          |  
|Total liabilities                                                                                                                                                            |  |               | 31,705   |   |                  |   | 31,291   |  
|                                                                                                                                                                             |  |               |          |   |                  |   |          |  
|Commitments and contingencies (Note 6)                                                                                                                                       |  |               |          |   |                  |   |          |  
|                                                                                                                                                                             |  |              
|Stockholders equity:                                                                                                                                                        |  |               |          |   |                  |   |          |  
|Preferred stock, par value $0.0001:Authorized: 10,000,000 shares Issued and outstanding: none                                                                                |  |               |         |   |                  |   |         |  
|Common stock, par value $0.0001:Authorized: 100,000,000 sharesIssued and outstanding: 25,520,663 and 25,273,623 shares at
March 31, 2009 and December 31, 2008, respectively |  |               | 3        |   |                  |   | 3        |  
|Additional paid-in capital                                                                                                                                                   |  |               | 213,526  |   |                  |   | 210,548  |  
|Deferred stock-based compensation                                                                                                                                            |  |               | (26      | ) |                  |   | (44      | )
|Accumulated other comprehensive income                                                                                                                                       |  |               | 1        |   |                  |   | 77       |  
|Accumulated deficit                                                                                                                                                          |  |               | (181,874 | ) |                  |   | (167,741 | )
|                                                                                                                                                                             |  |               |          |   |                  |   |          |  
|Total stockholders equity                                                                                                                                                   |  |               | 31,630   |   |                  |   | 42,843   |  
|                                                                                                                                                                             |  |               |          |   |                  |   |          |  
|Total liabilities and stockholders equity                                                                                                                                   |  | $             | 63,335   |   |                  | $ | 74,134   |  
|                                                                                                                                                                             |  |               |          |   |                  |   |          |  

The accompanying notes are an integral part of these condensed consolidated financial
statements.



1



---

##### Table of Contents

HANSEN MEDICAL, INC.

Condensed Consolidated Statements of Operations

(Unaudited)

(In thousands, except per share data)



|                                                            |  |                              |         |   |             |   |         |  
|----------------------------------------------------------- |  | ---------------------------- | ------- | - | ----------- | - | ------- | -
|                                                            |  | Three months ended March 31, |        
|                                                            |  | 2009                         |         |   | 2008        |  
|                                                            |  | As Restated                  |         |   | As Restated |  
|Revenues                                                    |  | $                            | 7,455   |   |             | $ | 4,623   |  
|Cost of goods sold                                          |  |                              | 5,381   |   |             |   | 4,537   |  
|                                                            |  |                              |         |   |             |   |         |  
|Gross profit                                                |  |                              | 2,074   |   |             |   | 86      |  
|                                                            |  |                              |         |   |             |   |         |  
|Operating expenses:                                         |  |                              |         |   |             |   |         |  
|Research and development                                    |  |                              | 5,651   |   |             |   | 5,214   |  
|Selling, general and administrative                         |  |                              | 10,111  |   |             |   | 8,077   |  
|                                                            |  |                              |         |   |             |   |         |  
|Total operating expenses                                    |  |                              | 15,762  |   |             |   | 13,291  |  
|                                                            |  |                              |         |   |             |   |         |  
|Loss from operations                                        |  |                              | (13,688 | ) |             |   | (13,205 | )
|Interest income                                             |  |                              | 130     |   |             |   | 408     |  
|Interest and other expense, net                             |  |                              | (575    | ) |             |   | (56     | )
|                                                            |  |                              |         |   |             |   |         |  
|Net loss                                                    |  | $                            | (14,133 | ) |             | $ | (12,853 | )
|                                                            |  |                              |         |   |             |   |         |  
|Basic and diluted net loss per share                        |  | $                            | (0.56   | ) |             | $ | (0.59   | )
|                                                            |  |                              |         |   |             |   |         |  
|Shares used to compute basic and diluted net loss per share |  |                              | 25,344  |   |             |   | 21,806  |  
|                                                            |  |                              |         |   |             |   |         |  

The accompanying notes are an integral part of these condensed consolidated financial
statements.



2



---

##### Table of Contents

HANSEN MEDICAL, INC.

Condensed Consolidated Statements of Cash Flows

(Unaudited)

(in thousands)



|                                                                            |  |                             |         |   |             |   |         |  
|--------------------------------------------------------------------------- |  | --------------------------- | ------- | - | ----------- | - | ------- | -
|                                                                            |  | Three months endedMarch 31, |        
|                                                                            |  | 2009                        |         |   | 2008        |  
|                                                                            |  | As Restated                 |         |   | As Restated |  
|Cash flows from operating activities:                                       |  |                             |         |   |             |   |         |  
|Net loss                                                                    |  | $                           | (14,133 | ) |             | $ | (12,853 | )
|Adjustments to reconcile net loss to net cash used in operating activities: |  |                             |         |   |             |   |         |  
|Depreciation and amortization                                               |  |                             | 1,107   |   |             |   | 349     |  
|Stock-based compensation                                                    |  |                             | 2,624   |   |             |   | 2,023   |  
|Amortization of preferred stock warrants                                    |  |                             |        |   |             |   | 14      |  
|Changes in operating assets and liabilities:                                |  |                             |         |   |             |   |         |  
|Accounts receivable                                                         |  |                             | 2,757   |   |             |   | (2,784  | )
|Inventories                                                                 |  |                             | 693     |   |             |   | (384    | )
|Deferred cost of goods sold                                                 |  |                             | 259     |   |             |   | (439    | )
|Prepaids and other current assets                                           |  |                             | 252     |   |             |   | (415    | )
|Other long-term assets                                                      |  |                             |        |   |             |   | (217    | )
|Accounts payable                                                            |  |                             | 493     |   |             |   | (807    | )
|Accrued liabilities                                                         |  |                             | 919     |   |             |   | 278     |  
|Deferred revenue                                                            |  |                             | (1,002  | ) |             |   | 1,596   |  
|Deferred rent                                                               |  |                             | (8      | ) |             |   | 14      |  
|Other long-term liabilities                                                 |  |                             | 48      |   |             |   | 11      |  
|                                                                            |  |                             |         |   |             |   |         |  
|Net cash used in operating activities                                       |  |                             | (5,991  | ) |             |   | (13,614 | )
|                                                                            |  |                             |         |   |             |   |         |  
|Cash flows from investing activities:                                       |  |                             |         |   |             |   |         |  
|Purchase of property and equipment                                          |  |                             | (255    | ) |             |   | (2,340  | )
|Proceeds from sales and maturities of short-term investments                |  |                             | 6,175   |   |             |   | 4,000   |  
|Purchase of investments                                                     |  |                             | (2,004  | ) |             |   |        |  
|                                                                            |  |                             |         |   |             |   |         |  
|Net cash provided by investing activities                                   |  |                             | 3,916   |   |             |   | 1,660   |  
|                                                                            |  |                             |         |   |             |   |         |  
|Cash flows from financing activities:                                       |  |                             |         |   |             |   |         |  
|Repayments of loans payable                                                 |  |                             |        |   |             |   | (513    | )
|Proceeds from exercise of common stock options, net                         |  |                             | 69      |   |             |   | 59      |  
|Proceeds from employee stock purchase plan                                  |  |                             | 300     |   |             |   | 604     |  
|                                                                            |  |                             |         |   |             |   |         |  
|Net cash provided by financing activities                                   |  |                             | 369     |   |             |   | 150     |  
|                                                                            |  |                             |         |   |             |   |         |  
|Net decrease in cash and cash equivalents                                   |  |                             | (1,706  | ) |             |   | (11,804 | )
|Cash and cash equivalents at beginning of period                            |  |                             | 17,377  |   |             |   | 30,404  |  
|                                                                            |  |                             |         |   |             |   |         |  
|Cash and cash equivalents at end of period                                  |  | $                           | 15,671  |   |             | $ | 18,600  |  
|                                                                            |  |                             |         |   |             |   |         |  
|Supplemental schedule of non-cash investing activities:                     |  |                             |         |   |             |   |         |  
|Unbilled construction costs incurred                                        |  | $                           |        |   |             | $ | 1,920   |  

The accompanying notes are an integral part of these condensed consolidated financial
statements.



3



---

##### Table of Contents

HANSEN MEDICAL, INC.

Notes to Condensed Consolidated Financial Statements

(Unaudited)

1. Description of Business

Hansen Medical, Inc. (the Company) develops, manufactures and markets a new generation of medical robotics designed for accurate
positioning, manipulation and stable control of catheters and catheter-based technologies. The Company was incorporated in the state of Delaware on September 23, 2002 and is headquartered in Mountain View, California. In March 2007, the Company
established Hansen Medical UK Ltd., a wholly-owned subsidiary located in the United Kingdom and, in May 2007, the Company established Hansen Medical, GmbH, a wholly-owned subsidiary located in Germany. Both subsidiaries were established for the
purpose of marketing the Companys products in Europe.

From inception to March 31, 2009, the Company has incurred
losses totaling approximately $181.9 million and has not generated positive cash flows from operations. The Company expects such losses to continue through at least the year ended December 31, 2009 as it continues to commercialize its
technologies and develop new applications and technologies. The Company also faces significant short-term uncertainty related to current economic and capital market conditions and the related impact of those conditions on the capital equipment
market.

On April 22, 2009, the Company sold 11,692,000 shares of its common stock, resulting in approximately $35.1
million of net proceeds, after underwriting discounts and commissions and estimated offering expenses. On August 25, 2008, the Company entered into a $25 million loan and security agreement with Silicon Valley Bank, consisting of a $15 million
term equipment line and a one-year $10 million revolving credit line. As of March 31, 2009, the Company had drawn down approximately $12.5 million against the term equipment line under this agreement. See Note 7.

If operating cash flows are significantly lower than current expectations, the Company may require capital in addition to the existing cash,
cash equivalents and short-term investment balances and the interest earned on those balances, in addition to the amounts available under the Companys revolving credit line, amounts received in its April 2009 stock offering and amounts
received through the sale of products. Any such required additional capital may not be available in amounts or on terms acceptable to the Company, if at all. This could leave the Company without adequate financial resources to fund its operations as
presently conducted or as it plans to conduct them in the future. If adequate funds are not available due to the Companys inability to obtain additional financing or if operating cash flows are insufficient to meet the Companys existing
debt covenants, the Company may be required to reduce the scope of, delay or eliminate some or all of its planned research, development and commercialization activities or to license to third parties the rights to commercialize products or
technologies that the Company would otherwise seek to commercialize. The Company might also have to reduce marketing, customer support or other resources devoted to its products. Any of these factors could harm its financial condition. Failure to
manage discretionary spending or raise additional capital as required may adversely impact the Companys ability to achieve its intended business objectives. The Company continues to evaluate the extent of its implemented cost-saving measures
based upon changing future economic conditions and the achievement of estimated revenue throughout 2009 and will consider the implementation of additional cost reductions during the remainder of the year if and as circumstances warrant.

2. Summary of Significant Accounting Policies

Basis of Presentation

The Company has prepared the accompanying
condensed consolidated financial statements in conformity with accounting principles generally accepted in the United States. The accompanying condensed consolidated financial statements and notes thereto are unaudited. In the opinion of the



4



---

##### Table of Contents

Companys management, these statements include all adjustments, which are of a normal recurring nature, necessary to present a fair presentation. Interim results are not necessarily
indicative of results for a full year or any other interim period. The condensed consolidated balance sheet as of December 31, 2008 was derived from audited financial statements, but does not include all disclosures required by accounting
principles generally accepted in the United States. The information included in this Form 10-Q/A should be read in conjunction with the Companys Annual Report on Form 10-K/A for the year ended December 31, 2008 as filed with the
Securities and Exchange Commission. The Companys fiscal year ends on December 31.

The accompanying condensed
consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. All significant intercompany balances and transactions have been eliminated in consolidation.

Use of Estimates

The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the amounts
reported in the financial statements and accompanying notes. Actual results could differ from those estimates.

Recent
Accounting Pronouncements

In December 2007, the Financial Accounting Standards Board (FASB) issued
Statement of Financial Accounting Standards (SFAS) No. 141 (revised 2007) Business Combinations (SFAS 141(R)). Under SFAS 141(R), in a business combination, an entity is required to recognize the assets acquired,
liabilities assumed, contractual contingencies, and contingent consideration at their fair value on the acquisition date. It further requires that acquisition-related costs be recognized separately from the acquisition and expensed as incurred; that
restructuring costs generally be expensed in periods subsequent to the acquisition date; and that changes in accounting for deferred tax asset valuation allowances and acquired income tax uncertainties after the measurement period be recognized as a
component of provision for taxes. In addition, acquired in-process research and development is capitalized as an intangible asset and amortized over its estimated useful life. For the Company, SFAS 141(R) is effective on a prospective basis for all
business combinations for which the acquisition date is on or after January 1, 2009 with the exception of the accounting for valuation allowances on deferred taxes and acquired contingencies under SFAS 109. The adoption of SFAS 141(R) did not
have a significant impact on the Companys consolidated financial statements. However, any future business combinations will be impacted by the new standard.

In December 2007, the FASB issued SFAS No. 160, Noncontrolling Interests in Consolidated Financial Statements (SFAS 160). SFAS 160 establishes accounting and reporting standards
for ownership interests in subsidiaries held by parties other than the parent, the amount of consolidated net income attributable to the parent and to the noncontrolling interest, changes in a parents ownership interest and the valuation of
retained noncontrolling equity investments when a subsidiary is deconsolidated. SFAS 160 also establishes reporting requirements that provide sufficient disclosures that clearly identify and distinguish between the interests of the parent and the
interests of the noncontrolling owners. SFAS 160 became effective for the Company beginning in the first quarter of 2009 and did not have a significant impact on its consolidated financial statements.

In November 2008, the FASB ratified Emerging Issues Task Force Issue No. 08-7, Accounting for Defensive Intangible Assets
(EITF 08-7). EITF 08-7 applies to defensive intangible assets, which are acquired intangible assets that the acquirer does not intend to actively use but intends to hold to prevent its competitors from obtaining access to them. As these
assets are separately identifiable, EITF 08-7 requires an acquiring entity to account for defensive intangible assets as a separate unit of accounting. Defensive intangible assets must be recognized at fair value in accordance with SFAS 141(R) and
SFAS 157. EITF 08-7 is effective for defensive intangible assets acquired in fiscal years beginning on or after December 15, 2008. The impact of the standard on the Companys financial position and results of operation will be dependent
upon the type of any acquisitions that are consummated in the future.



5



---

##### Table of Contents

In April 2009, the FASB issued FASB Staff Position SFAS 107-1 and APB No. 28-1,
Interim Disclosures about Fair Value of Financial Instruments. This FASB Staff Position amends FASB Statement No. 107, Disclosures about Fair Value of Financial Instruments, to require disclosures about the fair value of financial
instruments for interim reporting periods of publicly traded companies as well as in annual financial statements. This FASB Staff Position also amends APB Opinion No. 28, Interim Financial Reporting, to require those disclosures in
summarized financial information at interim reporting periods. This FASB Staff Position is effective for interim and annual periods ending after June 15, 2009. The Company is currently evaluating the disclosure requirements of FASB Staff
Position SFAS 107-1 and APB 28-1.

In April 2009, the FASB issued FASB Staff Position SFAS 157-4, Determining Fair Value
When the Volume and Level of Activity for the Asset or Liability Have Significantly Decreased and Identifying Transactions That Are Not Orderly, which provides additional guidance for estimating fair value in accordance with FASB Statement
No. 157, Fair Value Measurements, when the volume and level of activity for the asset or liability have significantly decreased. This FASB Staff Position also includes guidance on identifying circumstances that indicate a transaction is
not orderly. This pronouncement is effective for periods ending after June 15, 2009. The Company is currently evaluating the impact that FASB Staff Position SFAS 157-4 will have on its consolidated financial statements.

In April 2009, the FASB issued FASB Staff Position SFAS 115-2 and SFAS 124-2, Recognition and Presentation of Other-Than-Temporary
Impairments, to amend the other-than-temporary impairment guidance in debt securities to be based on intent to sell instead of ability to hold the security and to improve the presentation and disclosure of other-than-temporary impairments on
debt and equity securities in the financial statements. This pronouncement is effective for periods ending after June 15, 2009. The Company is currently evaluating the impact that FASB Staff Position SFAS 115-2 and SFAS 124-2 will have on its
consolidated financial statements.

3. Restatement of Financial Statements

In August 2009, the Company received an anonymous whistleblower report alleging a single irregularity that resulted in improper
revenue recognition in the quarter ended December 31, 2008. The Companys audit committee, with the assistance of independent outside counsel, undertook an investigation into the allegation and a review of the Companys historical
revenue recognition practices. The audit committees investigation determined that information was withheld from the Companys accounting department and independent auditors and documentation related to certain revenue transactions was
falsified. This led to incomplete information regarding temporary installations, unfulfilled training obligations, the inability of distributors to independently install systems and train end users, and undisclosed side arrangements. As a result,
there were instances where revenue was recognized prior to the completion of all of the elements required for revenue recognition under the Companys revenue recognition policy. All of the irregularities that were identified during the
investigation occurred outside of the accounting department.

The restatement of the Companys financial statements for
the three months ended March 31, 2009 and 2008 resulted from improper recognition of revenue prior to the completion of all of the elements required for revenue recognition under the Companys revenue recognition policy. Specifically, with
regard to one or more of these periods, improper revenue recognition resulted from recognition of revenue due to temporary installations of systems, unfulfilled training obligations and the inability of distributors to independently install systems
and train end users. The following table presents the impact of the restatement adjustments on the Companys Condensed Consolidated Balance Sheets as of March 31, 2009 and December 31, 2008:



6



---

##### Table of Contents



|                                     |  |                                       |          |   |                      |   |        |          |  |   |          |  
|------------------------------------ |  | ------------------------------------- | -------- | - | -------------------- | - | ------ | -------- |  | - | -------- | -
|                                     |  | March 31, 2009                        |         
|                                     |  | As PreviouslyReported                 |          |   | Effect ofRestatement |   |        | Restated | 
|                                     |  | (In thousands, except per share data) |         
|Assets                               |  |                                       |          |   |                      |   |        |          |  |   |          |  
|Deferred cost of goods sold          |  | $                                     |         |   |                      | $ | 2,105  |          |  | $ | 2,105    |  
|                                     |  |                                       |         
|Liabilities and Stockholders Equity |  |                                       |          |   |                      |   |        |          |  |   |          |  
|Current liabilities:                 |  |                                       |          |   |                      |   |        |          |  |   |          |  
|Accrued liabilities                  |  | $                                     | 6,870    |   |                      | $ | (300   | )        |  | $ | 6,570    |  
|Current portion of deferred revenue  |  | $                                     | 752      |   |                      | $ | 7,076  |          |  | $ | 7,828    |  
|Accumulated deficit                  |  | $                                     | (177,203 | ) |                      | $ | (4,671 | )        |  | $ | (181,874 | )
|                                     | 
|                                     |  | December 31, 2008                     |         
|                                     |  | As PreviouslyReported                 |          |   | Effect ofRestatement |   |        | Restated | 
|                                     |  | (In thousands, except per share data) |         
|Assets                               |  |                                       |          |   |                      |   |        |          |  |   |          |  
|Deferred cost of goods sold          |  | $                                     | 248      |   |                      | $ | 2,116  |          |  | $ | 2,364    |  
|                                     |  |                                       |         
|Liabilities and Stockholders Equity |  |                                       |          |   |                      |   |        |          |  |   |          |  
|Accrued liabilities                  |  | $                                     | 6,064    |   |                      | $ | (430   | )        |  | $ | 5,634    |  
|Current portion of deferred revenue  |  | $                                     | 1,386    |   |                      | $ | 7,408  |          |  | $ | 8,794    |  
|Accumulated deficit                  |  | $                                     | (162,879 | ) |                      | $ | (4,862 | )        |  | $ | (167,741 | )

The following table presents the impact of the restatement adjustments on the
Companys Condensed Consolidated Statements of Income for the three months ended March 31, 2009 and 2008:



|                                     |  |                                       |         |   |                      |   |        |          |  |   |         |  
|------------------------------------ |  | ------------------------------------- | ------- | - | -------------------- | - | ------ | -------- |  | - | ------- | -
|                                     |  | Three months endedMarch 31,
2009      |        
|                                     |  | As PreviouslyReported                 |         |   | Effect ofRestatement |   |        | Restated | 
|                                     |  | (In thousands, except per share data) |        
|Revenues                             |  | $                                     | 7,123   |   |                      | $ | 332    |          |  | $ | 7,455   |  
|Cost of goods sold                   |  | $                                     | 5,240   |   |                      | $ | 141    |          |  | $ | 5,381   |  
|Gross profit                         |  | $                                     | 1,883   |   |                      | $ | 191    |          |  | $ | 2,074   |  
|Net loss                             |  | $                                     | (14,324 | ) |                      | $ | 191    |          |  | $ | (14,133 | )
|Basic and diluted net loss per share |  | $                                     | (0.57   | ) |                      | $ | 0.01   |          |  | $ | (0.56   | )
|                                     | 
|                                     |  | Three months endedMarch 31,
2008      |        
|                                     |  | As PreviouslyReported                 |         |   | Effect ofRestatement |   |        | Restated | 
|                                     |  | (In thousands, except per share data) |        
|Revenues                             |  | $                                     | 6,244   |   |                      | $ | (1,621 | )        |  | $ | 4,623   |  
|Cost of goods sold                   |  | $                                     | 4,937   |   |                      | $ | (400   | )        |  | $ | 4,537   |  
|Gross profit                         |  | $                                     | 1,307   |   |                      | $ | (1,221 | )        |  | $ | 86      |  
|Net loss                             |  | $                                     | (11,632 | ) |                      | $ | (1,221 | )        |  | $ | (12,853 | )
|Basic and diluted net loss per share |  | $                                     | (0.53   | ) |                      | $ | (0.06  | )        |  | $ | (0.59   | )



7



---

##### Table of Contents

The following table presents the impact of the restatement adjustments on the Companys
Condensed Consolidated Statements of Comprehensive Income for the three months ended March 31, 2009 and 2008:



|                   |  |                                   |         |   |                      |   |        |          |  |   |         |  
|------------------ |  | --------------------------------- | ------- | - | -------------------- | - | ------ | -------- |  | - | ------- | -
|                   |  | Three months ended March 31, 2009 |        
|                   |  | As PreviouslyReported             |         |   | Effect ofRestatement |   |        | Restated | 
|Net loss           |  | $                                 | (14,324 | ) |                      | $ | 191    |          |  | $ | (14,133 | )
|Comprehensive loss |  | $                                 | (14,400 | ) |                      | $ | 191    |          |  | $ | (14,209 | )
|                   | 
|                   |  | Three Months Ended March 31, 2008 |        
|                   |  | As PreviouslyReported             |         |   | Effect ofRestatement |   |        | Restated | 
|Net loss           |  | $                                 | (11,632 | ) |                      | $ | (1,221 | )        |  | $ | (12,853 | )
|Comprehensive loss |  | $                                 | (11,577 | ) |                      | $ | (1,221 | )        |  | $ | (12,798 | )
|                   |  |                                   |         |   |                      |   |        |          |  |   |         |  

All adjustments relate to the deferral of revenue and the associated cost of goods
sold and warranty expenses and the recognition of revenue and the associated expenses related to sales deferred from earlier periods as a result of the restatement. The restatement adjustments did not impact the total net cash flows from operating,
financing, or investing activities in the Condensed Consolidated Statements of cash flows for the quarterly periods ended March 31, 2009 and 2008. All notes to the consolidated financial statements affected by the restatements have been labeled
as restated.

4. Investments and Fair Value Measurements

The amortized cost and fair value of cash equivalents and short-term investments, with gross unrealized gains and losses, were as follows (in thousands):



|                                  |  |               |        |                      |   |                       |  |                       |            |   |                             |   |        |  |   |        |  |   |       
|--------------------------------- |  | ------------- | ------ | -------------------- | - | --------------------- |  | --------------------- | ---------- | - | --------------------------- | - | ------ |  | - | ------ |  | - | ------
|                                  |  | AmortizedCost |        | GrossUnrealizedGains |   | GrossUnrealizedLosses |  |                       | Fair Value |   | Balance SheetClassification
|                                  |  |               |        |                      |   | CashEquivalents       |  | Short-termInvestments
|As of March 31, 2009:             |  |               |        |                      |   |                       |  |                       |            |   |                             |   |        |  |   |        |  |   |       
|Money market funds                |  | $             | 11,933 |                      | $ |                      |  | $                     |           |   |                             | $ | 11,933 |  | $ | 11,933 |  | $ |      
|U.S. government agency securities |  |               | 9,994  |                      |   | 52                    |  |                       | (1         | ) |                             |   | 10,045 |  |   |       |  |   | 10,045
|Corporate debt securities         |  |               | 3,527  |                      |   | 12                    |  |                       |           |   |                             |   | 3,539  |  |   |       |  |   | 3,539 
|                                  |  |               |        |                      |   |                       |  |                       |            |   |                             |   |        |  |   |        |  |   |       
|                                  |  | $             | 25,454 |                      | $ | 64                    |  | $                     | (1         | ) |                             | $ | 25,517 |  | $ | 11,933 |  | $ | 13,584
|                                  |  |               |        |                      |   |                       |  |                       |            |   |                             |   |        |  |   |        |  |   |       
|As of December 31, 2008:          |  |               |        |                      |   |                       |  |                       |            |   |                             |   |        |  |   |        |  |   |       
|Money market funds                |  | $             | 7,486  |                      | $ |                      |  | $                     |           |   |                             | $ | 7,486  |  | $ | 7,486  |  | $ |      
|U.S. government agency securities |  |               | 10,992 |                      |   | 108                   |  |                       |           |   |                             |   | 11,100 |  |   |       |  |   | 11,100
|Corporate debt securities         |  |               | 11,820 |                      |   | 22                    |  |                       |           |   |                             |   | 11,842 |  |   | 5,096  |  |   | 6,746 
|                                  |  |               |        |                      |   |                       |  |                       |            |   |                             |   |        |  |   |        |  |   |       
|                                  |  | $             | 30,298 |                      | $ | 130                   |  | $                     |           |   |                             | $ | 30,428 |  | $ | 12,582 |  | $ | 17,846
|                                  |  |               |        |                      |   |                       |  |                       |            |   |                             |   |        |  |   |        |  |   |       



8



---

##### Table of Contents

Fixed income securities included in short-term investments above are summarized by their
contractual maturities as follows (in thousands):



|                        |  |               |        |                  |   |       
|----------------------- |  | ------------- | ------ | ---------------- | - | ------
|                        |  | March 31,2009 |        | December 31,2008
|Contractual maturities: |  |               |        |                  |   |       
|Less than one year      |  | $             | 12,057 |                  | $ | 16,308
|One to two years        |  |               | 1,527  |                  |   | 1,538 
|                        |  |               |        |                  |   |       
|                        |  | $             | 13,584 |                  | $ | 17,846
|                        |  |               |        |                  |   |       

The Company periodically assesses whether significant facts and circumstance have
arisen to indicate that an impairment, that is other than temporary, of the fair value of any underlying investment has occurred. The investments held by the Company are high investment grade and, as of March 31, 2009, investments which are in
an unrealized loss position are summarized as follows (in thousands):



|                                 |  |            |       |                       |   |    |  
|-------------------------------- |  | ---------- | ----- | --------------------- | - | -- | -
|                                 |  | Fair Value |       | GrossUnrealizedLosses |  
|U.S government agency securities |  | $          | 1,998 |                       | $ | (1 | )
|                                 |  |            |       |                       |   |    |  
|                                 |  | $          | 1,998 |                       | $ | (1 | )
|                                 |  |            |       |                       |   |    |  

None of the above investments have contractual maturities of more than one year and
no investments have been in an unrealized loss position for longer than twelve months.

The gross unrealized losses on
investments were due primarily to changes in interest rates and other market conditions as well as to changes in the credit conditions of the underlying securities. These investments are not considered other-than-temporarily impaired as the gross
losses are minor and the Company has the ability to hold substantially all of these investments until maturity or until a recovery of fair value occurs.

Fair Value Measurements

Accounting principles generally accepted in
the United States define fair value as an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based
measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. As a basis for considering such assumptions, inputs used in measuring fair value are prioritized as follows:



|                        |  |                                                                                                                 
|----------------------- |  | ----------------------------------------------------------------------------------------------------------------
|        Level 1 Inputs |  | Quoted prices (unadjusted) in active markets for identical assets or liabilities.                               
|                        | 
|        Level 2 Inputs |  | Inputs other than quoted prices in active markets that are observable either directly or indirectly.            
|                        | 
|        Level 3 Inputs |  | Unobservable inputs in which there is little or no market data, which require us to develop our own assumptions.

This hierarchy requires the use of observable market data when available and to
minimize the use of unobservable inputs when determining fair value. The Companys cash equivalent and short-term investment instruments are classified using Level 1 or Level 2 inputs within the fair value hierarchy because they are valued
using quoted market prices, broker or dealer quotations, or alternative pricing sources with reasonable levels of price transparency. Investment instruments valued using Level 1 inputs include money market securities and U.S. government agency
securities. Investment instruments valued using Level 2 inputs include investment-grade corporate debts, such as bonds and commercial paper.



9



---

##### Table of Contents

The fair value hierarchy of our cash equivalents and short-term investments at
March 31, 2009 is as follows (in thousands):



|                                  |  |                                                                   |        |                                                   |   |       |  |   |       
|--------------------------------- |  | ----------------------------------------------------------------- | ------ | ------------------------------------------------- | - | ----- |  | - | ------
|                                  |  | Fair Value Measurements Using                                     |        | Total                                            
|                                  |  | Quoted Prices inActive Marketsfor
IdenticalAssets(Level 1 Inputs) |        | Significant otherObservableInputs(Level 2 Inputs) |  
|Money market funds                |  | $                                                                 | 11,933 |                                                   | $ |      |  | $ | 11,933
|U.S. government agency securities |  |                                                                   | 10,045 |                                                   |   |      |  |   | 10,045
|Corporate debt securities         |  |                                                                   |       |                                                   |   | 3,539 |  |   | 3,539 
|                                  |  |                                                                   |        |                                                   |   |       |  |   |       
|                                  |  | $                                                                 | 21,978 |                                                   | $ | 3,539 |  | $ | 25,517
|                                  |  |                                                                   |        |                                                   |   |       |  |   |       

5. Inventories (in thousands)



|                |  |               |       |                  |   |      
|--------------- |  | ------------- | ----- | ---------------- | - | -----
|                |  | March 31,2009 |       | December 31,2008
|                |  | As Restated   |       |                 
|Raw materials   |  | $             | 1,983 |                  | $ | 1,984
|Work in process |  |               | 2,784 |                  |   | 2,980
|Finished goods  |  |               | 966   |                  |   | 1,462
|                |  |               |       |                  |   |      
|Inventories     |  | $             | 5,733 |                  | $ | 6,426
|                |  |               |       |                  |   |      

6. Commitments and Contingencies

Operating Commitments

The Company rents its office and laboratory facilities under operating leases which expire at various dates through November 2014. The Company has an option to extend its main lease until approximately
November 30, 2019. As of March 31, 2009, annual contractual commitments associated with lease obligations were as follows (in thousands):



|                  |  |   |       
|----------------- |  | - | ------
|Remainder of 2009 |  | $ | 1,359 
|2010              |  |   | 1,743 
|2011              |  |   | 1,784 
|2012              |  |   | 1,838 
|2013              |  |   | 1,893 
|Thereafter        |  |   | 1,783 
|                  |  |   |       
|Total             |  | $ | 10,400
|                  |  |   |       



10



---

##### Table of Contents

Warranties

The Company generally provides a limited one-year warranty on its Sensei system and accrues the estimated cost of warranties at the time
revenue is recognized. The Companys warranty obligation may be impacted by product failure rates, material usage and service costs associated with its warranty obligations. The Company periodically evaluates and adjusts the warranty reserve to
the extent actual warranty expense differs from the original estimates. Movement in warranty liability was as follows (in thousands):



|                                                 |  |                             |      |   |             |   |      |  
|------------------------------------------------ |  | --------------------------- | ---- | - | ----------- | - | ---- | -
|                                                 |  | Three months endedMarch 31, |     
|                                                 |  | 2009                        |      |   | 2008        |  
|                                                 |  | As Restated                 |      |   | As Restated |  
|Balance at beginning of period                   |  | $                           | 881  |   |             | $ | 488  |  
|Accruals for warranties issued during the period |  |                             | 387  |   |             |   | 318  |  
|                                                 |  |                             |      |   |             |   |      |  
|Warranty costs incurred during the period        |  |                             | (428 | ) |             |   | (216 | )
|                                                 |  |                             |      |   |             |   |      |  
|Balance at end of period                         |  | $                           | 840  |   |             | $ | 590  |  
|                                                 |  |                             |      |   |             |   |      |  

Legal Proceedings

On June 22, 2007, the Company filed suit in Santa Clara Superior Court against Luna Innovations Incorporated (Luna) alleging
that Luna has, among other things, breached a 2006-2007 development and intellectual property agreement with the Company that the Company believes establishes its ownership of all intellectual property in medical robotics developed by the parties
during performance of the agreement, misappropriated the Companys trade secrets and has revealed confidential information of the Company to other companies who might improperly benefit from it. On April 21, 2009, after an approximately
four week trial, a jury awarded the Company approximately $36.3 million in damages, finding in favor of the Company on its breach of contract, breach of the covenant of good faith and fair dealing, and misappropriation of trade secrets claims
against Luna. The jury did not find in the Companys favor on its fraud claims against Luna, but did find that Lunas misappropriation was willful or malicious. The verdict and recovery of damages is subject to customary post-trial motions
and appeals, as well as collection risks.

7. Long-term Debt

In August 2008, the Company entered into a $25 million loan and security agreement with Silicon Valley Bank, consisting of a $15 million term
equipment line due in installments from April 2009 through September 2012 bearing annual interest equal to the U.S. Treasury note yield to maturity plus 3.5%, and a one-year $10 million revolving credit line, bearing interest at a floating per annum
rate equal to the Prime Rate plus 1%. The interest rate on borrowings under the equipment line becomes fixed for each borrowing at the time of the draw-down. The interest rate on borrowings under the one-year revolving credit line adjusts with the
banks Prime Rate. The loans are collateralized by substantially all of the Companys assets, excluding intellectual property, and are subject to certain covenants which, if not met, could constitute an event of default. These covenants
include maintaining the required liquidity, achieving the specified EBITDA amounts, the non-occurrence of a material adverse change (defined as a material impairment in the perfection or priority of the banks lien in the collateral or in the
value of the collateral, a material adverse change in the business, operations or conditions (financial or otherwise) of the Company, or a material impairment of the prospect of repayment of any portion of the Companys outstanding obligations)
and fulfilling certain reporting requirements. The liquidity covenants require the Company to maintain at the end of each month either liquid assets in the amount of 1.5 times the outstanding loan balance or sufficient liquidity to fund at least six
months of projected operations, whichever is greater. The Company will become subject to EBITDA requirements beginning with the second quarter of 2009. The Company and Silicon Valley Bank have yet to determine the quarterly EBITDA amounts. As of
March 31, 2009, the Company was in compliance with all financial covenants. The Company has drawn down approximately $12.5 million against the term equipment line at an interest rate of 6.12% and, as of March 31, 2009, the remainder of
this line is no longer available per the original agreement terms.



11



---

##### Table of Contents

Future annual payments due on the amounts outstanding as of March 31, 2009 are as
follows (in thousands):



|                                   |  |   |        |  
|---------------------------------- |  | - | ------ | -
|Remainder of 2009                  |  | $ | 2,978  |  
|2010                               |  |   | 3,970  |  
|2011                               |  |   | 3,970  |  
|2012                               |  |   | 3,726  |  
|                                   |  |   |        |  
|                                   |  |   | 14,644 |  
|Less: Amount representing interest |  |   | (2,168 | )
|                                   |  |   |        |  
|                                   |  |   | 12,476 |  
|Less: Current portion              |  |   | (3,290 | )
|                                   |  |   |        |  
|Long Term Portion                  |  | $ | 9,186  |  
|                                   |  |   |        |  

8. Stockholders Equity

Stock-based Compensation

The Company recognizes compensation expense for its stock-based awards in accordance with SFAS No. 123  revised 2004, Share-Based Payment. Employee and non-employee stock-based
compensation expense for stock-based awards under the Companys 2002 Stock Option Plan, 2006 Equity Incentive Plan and 2006 Employee Stock Purchase Plan was allocated as follows (in thousands):



|                                    |  |                             |       |      |   |      
|----------------------------------- |  | --------------------------- | ----- | ---- | - | -----
|                                    |  | Three months endedMarch 31,
|                                    |  | 2009                        |       | 2008
|Cost of goods sold                  |  | $                           | 223   |      | $ | 161  
|Research and development            |  |                             | 620   |      |   | 570  
|Selling, general and administrative |  |                             | 1,781 |      |   | 1,292
|                                    |  |                             |       |      |   |      
|Total                               |  | $                           | 2,624 |      | $ | 2,023
|                                    |  |                             |       |      |   |      

The Company uses the Black-Scholes pricing model to determine the fair value of stock
options. The determination of the fair value of stock-based payment awards on the date of grant is affected by our stock price as well as assumptions regarding a number of complex and subjective variables. These variables include our expected stock
price volatility over the term of the awards, actual and projected employee stock option exercise behaviors, risk-free interest rates and expected dividends. The estimated grant date fair values of the employee stock options for the periods
presented were calculated using the Black-Scholes valuation model, based on the following assumptions:



|                         |  |                             |   |  |      |  
|------------------------ |  | --------------------------- | - |  | ---- | -
|                         |  | Three months endedMarch 31, |  
|Employee Stock Options:  |  | 2009                        |   |  | 2008 |  
|Expected volatility      |  | 58.0                        | % |  | 51.0 | %
|Risk-free interest rate  |  | 1.9                         | % |  | 2.9  | %
|Expected term (in years) |  | 4.75                        |   |  | 5.00 |  
|Expected dividend rate   |  | 0                           | % |  | 0    | %



12



---

##### Table of Contents

Stock-based compensation expense related to stock options granted to non-employees is
recognized on an accelerated basis as the stock options are earned. The Company believes that the fair value of the stock options is more reliably measurable than the fair value of the services received. The fair value of the stock options granted
to non-employees is calculated at each reporting date using the Black-Scholes option pricing model, using the following assumptions:



|                            |  |                              |  |            
|--------------------------- |  | ---------------------------- |  | -----------
|                            |  | Three months ended March 31,
|Non-Employee Stock Options: |  | 2009                         |  | 2008       
|Expected volatility         |  | 59.0%-63.0%                  |  | 55.0%-61.0%
|Risk-free interest rate     |  | 1.7%-2.4%                    |  | 2.7%-4.1%  
|Contractual term (in years) |  | 5.00-7.75                    |  | 6.00-8.75  
|Expected dividend rate      |  | 0%                           |  | 0%         

The estimated fair values of the shares issued under the Companys Employee
Stock Purchase Plan were calculated using the following assumptions:



|                              |  |                             |   |  |      |  
|----------------------------- |  | --------------------------- | - |  | ---- | -
|                              |  | Three months endedMarch 31, |  
|Employee Stock Purchase Plan: |  | 2009                        |   |  | 2008 |  
|Expected volatility           |  | 126.4                       | % |  | 50.6 | %
|Risk-free interest rate       |  | 0.4                         | % |  | 3.5  | %
|Expected term (in years)      |  | 0.50                        |   |  | 0.50 |  
|Expected dividend rate        |  | 0                           | % |  | 0    | %

Stock Option and Equity Incentive Plans

Option activity under the Companys 2002 Stock Option Plan and 2006 Equity Incentive Plan was as follows:



|                                 |  |                    |   |  |                                |       |                                          |      |                          |   |      
|-------------------------------- |  | ------------------ | - |  | ------------------------------ | ----- | ---------------------------------------- | ---- | ------------------------ | - | -----
|                                 |  | OptionsOutstanding |   |  | Weighted-AverageExercise Price |       | Weighted-AverageRemainingContractualTerm |      | AggregateIntrinsic Value
|                                 |  | (In thousands)     |   |  |                                |       | (In years)                               |      | (In thousands)          
|Balances, December 31, 2008      |  | 4,203              |   |  | $                              | 12.33 |                                          |      |                          |   |      
|Options granted                  |  | 740                |   |  | $                              | 3.26  |                                          |      |                          |   |      
|Options exercised                |  | (29                | ) |  | $                              | 2.38  |                                          |      |                          |   |      
|Options cancelled                |  | (580               | ) |  | $                              | 11.84 |                                          |      |                          |   |      
|                                 |  |                    |   |  |                                |       |                                          |      |                          |   |      
|Balances, March 31, 2009         |  | 4,334              |   |  | $                              | 10.91 |                                          | 6.20 |                          | $ | 2,187
|                                 |  |                    |   |  |                                |       |                                          |      |                          |   |      
|Options vested at March 31, 2009 |  | 1,737              |   |  | $                              | 10.45 |                                          | 6.24 |                          | $ | 1,317
|                                 |  |                    |   |  |                                |       |                                          |      |                          |   |      

As of March 31, 2009, total unamortized stock-based compensation related to
unvested stock options was $11,367,000, with a weighted-average recognition period of 2.71 years.

Restricted stock unit
activity under the 2006 Equity Incentive Plan is as follows:



|                                            |  |                                  |   |  |                                        |      
|------------------------------------------- |  | -------------------------------- | - |  | -------------------------------------- | -----
|                                            |  | Restricted StockUnitsOutstanding |   |  | Weighted-Average FairValue WhenAwarded
|                                            |  | (In thousands)                   |   |  |                                       
|Restricted stock units at December 31, 2008 |  | 40                               |   |  | $                                      | 12.50
|Awarded                                     |  | 125                              |   |  | $                                      | 5.00 
|Vested                                      |  | (130                             | ) |  | $                                      | 5.11 
|                                            |  |                                  |   |  |                                        |      
|Restricted stock units at March 31, 2009    |  | 35                               |   |  | $                                      | 13.17
|                                            |  |                                  |   |  |                                        |      



13



---

##### Table of Contents

As of March 31, 2009, there was approximately $154,000 of unrecognized compensation
costs related to restricted stock units which is expected to be recognized over a weighted-average period of 0.65 years.

As
of March 31, 2009, 1,387,000 shares of common stock were available for grant under the 2006 Equity Incentive Plan.

9. Income Taxes

A reconciliation of the beginning and ending balance of unrecognized tax benefits related to uncertain tax positions is as
follows (in thousands):



|                                                             |  |                             |     |      |   |    
|------------------------------------------------------------ |  | --------------------------- | --- | ---- | - | ---
|                                                             |  | Three months endedMarch 31,
|                                                             |  | 2009                        |     | 2008
|Balance at beginning of period                               |  | $                           | 810 |      | $ | 600
|Additions based on tax positions related to the current year |  |                             | 47  |      |   |   
|                                                             |  |                             |     |      |   |    
|Balance at end of period                                     |  | $                           | 857 |      | $ | 600
|                                                             |  |                             |     |      |   |    

If the Company is able to eventually recognize these uncertain tax positions, all of
the unrecognized benefit would reduce the Companys effective tax rate. The Company currently has a full valuation allowance against its net deferred tax asset which would impact the timing of the effective tax rate benefit should any of these
uncertain tax positions be favorably settled in the future.

10. Net Loss Per Share

The following table sets forth the computation of basic and diluted net loss per share (in thousands, except per share data):



|                                                               |  |                             |         |   |             |   |         |  
|-------------------------------------------------------------- |  | --------------------------- | ------- | - | ----------- | - | ------- | -
|                                                               |  | Three months endedMarch 31, |        
|                                                               |  | 2009                        |         |   | 2008        |  
|                                                               |  | As Restated                 |         |   | As Restated |  
|Net loss                                                       |  | $                           | (14,133 | ) |             | $ | (12,853 | )
|                                                               |  |                             |         |   |             |   |         |  
|Weighted-average common shares outstanding                     |  |                             | 25,350  |   |             |   | 21,877  |  
|Weighted-average unvested common shares subject to repurchase  |  |                             | (6      | ) |             |   | (71     | )
|                                                               |  |                             |         |   |             |   |         |  
|Shares used to calculated basic and diluted net loss per share |  |                             | 25,344  |   |             |   | 21,806  |  
|                                                               |  |                             |         |   |             |   |         |  
|Basic and diluted net loss per share                           |  | $                           | (0.56   | ) |             | $ | (0.59   | )
|                                                               |  |                             |         |   |             |   |         |  

The following table sets forth potential shares of common stock that are not included
in the calculation of diluted net loss per share because to do so would be anti-dilutive as of the end of each period presented (in thousands):



|                                             |  |           |  |      
|-------------------------------------------- |  | --------- |  | -----
|                                             |  | March 31,
|                                             |  | 2009      |  | 2008 
|Stock options outstanding                    |  | 4,334     |  | 3,381
|Unvested restricted stock units              |  | 35        |  | 15   
|Unvested common shares subject to repurchase |  | 4         |  | 53   



14



---

##### Table of Contents

11. Comprehensive Loss

Total comprehensive loss was as follows (in thousands):



|                                                     |  |                              |         |   |             |   |         |  
|---------------------------------------------------- |  | ---------------------------- | ------- | - | ----------- | - | ------- | -
|                                                     |  | Three months ended March 31, |        
|                                                     |  | 2009                         |         |   | 2008        |  
|                                                     |  | As Restated                  |         |   | As Restated |  
|Net loss                                             |  | $                            | (14,133 | ) |             | $ | (12,853 | )
|Other comprehensive income (loss):                   |  |                              |         |   |             |   |         |  
|Change in unrealized gains and losses on investments |  |                              | (70     | ) |             |   | 51      |  
|Foreign currency translation adjustment              |  |                              | (6      | ) |             |   | 4       |  
|                                                     |  |                              |         |   |             |   |         |  
|Comprehensive loss                                   |  | $                            | (14,209 | ) |             | $ | (12,798 | )
|                                                     |  |                              |         |   |             |   |         |  

12. Subsequent Events

On April 21, 2009, a jury awarded the Company approximately $36.3 million in damages in connection with its litigation against Luna,
finding in favor of the Company on its breach of contract, breach of the covenant of good faith and fair dealing, and misappropriation of trade secrets claims against Luna. The jury did not find in the Companys favor on its fraud claims
against Luna, but did find that Lunas misappropriation was willful or malicious. The verdict and recovery of damages is subject to customary post-trial motions and appeals, as well as collection risks.

On April 22, 2009, the Company sold 11,692,000 shares of its common stock, resulting in approximately $35.1 million of net proceeds to
the Company, after underwriting discounts and commissions and estimated offering expenses.



15



---

##### Table of Contents

ITEM 2. MANAGEMENTS DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND
RESULTS OF OPERATIONS (Restated)

The following discussion should be read in conjunction with the condensed consolidated
financial statements and notes thereto appearing elsewhere in this Quarterly Report on Form 10-Q/A.

Except for the
historical information contained herein, the matters discussed in this Managements Discussion and Analysis of Financial Condition and Results of Operations, are forward-looking statements that involve risks and uncertainties. In
some cases, these statements may be identified by terminology such as may, will, should, expects, could, intends, might, plans, anticipates,
believes, estimates, predicts, potential, or continue, or the negative of such terms and other comparable terminology. These statements involve known and unknown risks and uncertainties
that may cause our results, levels of activity, performance or achievements to be materially different from those expressed or implied by the forward-looking statements. Factors that may cause or contribute to such differences include, among others,
those discussed in this report in Part II, Item 1A Risk Factors. Except as may be required by law, we undertake no obligation to update any forward-looking statement to reflect events after the date of this report.

Overview

The following
discussion of our financial condition and results of operations should be read in conjunction with our consolidated financial statements and the related notes thereto included elsewhere in this amended quarterly report on Form 10-Q/A, and gives
effect to the restatement of our consolidated financial statements as discussed in Note 3 of the condensed consolidated financial statements.

We develop, manufacture and sell a new generation of medical robotics designed for accurate positioning, manipulation and stable control of catheters and catheter-based technologies. Our Sensei Robotic Catheter System, or Sensei system, is designed to allow physicians to instinctively navigate flexible
catheters with greater stability and control in interventional procedures. We believe our Sensei system and its corresponding disposable Artisan catheter will enable physicians to perform procedures that historically have been too difficult or time
consuming to accomplish routinely with manually-controlled, hand-held catheters and catheter-based technologies, or that we believe could be accomplished only by the most skilled physicians. We believe that our Sensei system has the potential to
benefit patients, physicians, hospitals and third-party payors by improving clinical outcomes and permitting more complex procedures to be performed interventionally.

We were incorporated in Delaware on September 23, 2002. In March 2007, we established Hansen Medical UK Ltd, a wholly-owned subsidiary located in the United Kingdom and, in May 2007, we established
Hansen Medical Deutschland, GmbH, a wholly-owned subsidiary located in Germany. Since inception, we have devoted the majority of our resources to the development and commercialization of our Sensei system.

To date, we have incurred net losses in each year since our inception and, as of March 31, 2009, we had an accumulated deficit of
$181.9 million. We expect our losses to continue through at least 2009 as we continue to expand the commercialization of our Sensei system and Artisan catheter and continue to develop new products. We have financed our operations primarily through
the sale of public and private equity securities and the issuance of debt. Most recently, on April 22, 2009, we sold 11,692,000 shares of our common stock, resulting in approximately $35.1 million of net proceeds, after underwriting discounts
and commissions and estimated offering expenses.

We received CE Mark approval for our Sensei system in the fourth quarter of
2006 and made our first commercial shipments to the European Union in the first quarter of 2007. In May 2007, we received CE Mark approval for our Artisan catheter and also received FDA clearance for the marketing of our Sensei system and Artisan
catheter for manipulation, positioning and control of certain mapping catheters during electrophysiology procedures. As a result, we recorded our first revenues in the second quarter of 2007. We have also received regulatory approvals in Russia and
Australia.



16



---

##### Table of Contents

We market our products in the United States primarily through a direct sales force of
regional sales employees, supported by clinical account managers who provide training, clinical support and other services to our customers. Outside the United States, primarily in the European Union, we use a combination of a direct sales force and
distributors to market, sell and support our products.

Critical Accounting Policies, Estimates and Judgments

We prepare our consolidated financial statements in accordance with accounting principles generally accepted in the United States. In doing
so, we have to make estimates and assumptions that affect our reported amounts of assets, liabilities, revenues and expenses, as well as related disclosures of contingent assets and liabilities. In many cases, we could reasonably have used different
accounting policies and estimates. In some cases, changes in the accounting estimates are reasonably likely to occur from period to period. Accordingly, actual results could differ materially from our estimates. We base our estimates on our past
experience and on other assumptions that we believe are reasonable under the circumstances, and we evaluate these estimates on an ongoing basis. To the extent that there are material differences between these estimates and actual results, our
financial condition or results of operations will be affected. Our significant accounting policies are fully described in Note 2 to our Financial Statements included in our Annual Report on Form 10-K/A for the year ended December 31, 2008 filed
with the U.S. Securities and Exchange Commission. There have been no significant changes to those policies in the three months ended March 31, 2009.

Financial Overview

Revenues

Our revenues consist of sales of Sensei systems, Artisan catheters, other disposables and service contracts. We have experienced significant
fluctuations in quarterly revenues, primarily due to still being in the early stages of our commercial launch and, especially in the fourth quarter of 2008 and the first quarter of 2009, general economic and capital market conditions. We expect
these fluctuations to continue throughout 2009, even as we plan to experience overall revenue growth as compared to 2008 levels. We do not anticipate that revenues in 2009 will be sufficient to eliminate losses.

Cost of Goods Sold

Cost of goods sold consists primarily of materials, direct labor, depreciation, overhead costs associated with manufacturing, training and installation costs, royalties, provisions for inventory
valuation, service contract expenses and warranty expenses. We expect that cost of goods sold both as a percentage of revenue and on a dollar basis will continue to vary from quarter to quarter in 2009 due, among other things, to fluctuations in
revenue levels, average selling prices, the mix of products sold, manufacturing levels and manufacturing yields.

Research and Development Expenses

Our research and development expenses primarily consist of
engineering, software development, product development, quality assurance and clinical and regulatory expenses, including costs to develop our Sensei system and disposable Artisan catheters. Research and development expenses include employee
compensation, including stock-based compensation expense, consulting services, outside services, materials, supplies, depreciation and travel. We expense research and development costs as they are incurred. We expect research and development
expenses for the remainder of 2009 to decrease as compared to 2008 levels as we reduce our employee costs, experience the effects of quarterly one-week furloughs and carefully manage expenses related to our development activities for the
electrophysiology market and exploring certain other potential future applications of our technology.



17



---

##### Table of Contents

Selling, General and Administrative Expenses

Our selling, general and administrative expenses consist primarily of compensation for executive, finance, sales, legal and administrative
personnel, including sales commissions and stock-based compensation. Other significant expenses include costs associated with attending medical conferences, professional fees for legal services (including legal services associated with our efforts
to obtain and maintain broad protection for the intellectual property related to our products) and accounting services, consulting fees and travel expenses. We expect our selling, general and administrative expenses for the remainder of 2009 to
decrease as compared to 2008 levels as we reduce general and administrative employee costs while we continue to maintain our sales and clinical support groups and experience the effects of quarterly one-week furloughs.

Results of Operations

Comparison of the
three months ended March 31, 2009 to the three months ended March 31, 2008

Revenues



|                       |  |                              |       |             |   |             |  |             |       |  |    |  
|---------------------- |  | ---------------------------- | ----- | ----------- | - | ----------- |  | ----------- | ----- |  | -- | -
|                       |  | Three months ended March 31, |       | Change      |  
|(Dollars in thousands) |  | 2009                         |       | 2008        |   | $           |  | %           |      
|                       |  | As Restated                  |       | As Restated |   | As Restated |  | As Restated |      
|Revenues               |  | $                            | 7,455 |             | $ | 4,623       |  | $           | 2,832 |  | 61 | %

Revenues primarily related to the following:



|                                                      |  |                             |     |             |   |    
|----------------------------------------------------- |  | --------------------------- | --- | ----------- | - | ---
|                                                      |  | Three months endedMarch 31,
|                                                      |  | 2009                        |     | 2008       
|                                                      |  | As Restated                 |     | As Restated
|United States Sensei system units                     |  |                             | 8   |             |   | 5  
|International Sensei system units                     |  |                             | 2   |             |   | 1  
|                                                      |  |                             |     |             |   |    
|Total Sensei system units                             |  |                             | 10  |             |   | 6  
|                                                      |  |                             |     |             |   |    
|Sensei system average selling price (in thousands)    |  | $                           | 610 |             | $ | 641
|                                                      |  |                             |     |             |   |    
|Artisan catheter units                                |  |                             | 631 |             |   | 401
|                                                      |  |                             |     |             |   |    
|Artisan catheter average selling price (in thousands) |  | $                           | 1.6 |             | $ | 1.8
|                                                      |  |                             |     |             |   |    

Our average selling prices of Sensei systems in the first quarter of 2009 were
negatively impacted by the sale of two international systems, which tend to generate lower average selling prices and by general economic and capital market conditions. We have experienced significant fluctuations in quarterly revenues, primarily
due to the fact that we are still in the early stages of our commercial launch and, especially in the fourth quarter of 2008 and the first quarter of 2009, general economic and capital market conditions. During the fourth quarter of 2008 and into
the first quarter of 2009, in a period of economic uncertainty, we saw many potential customers lengthen their sales cycles and postpone purchase decisions. We expect these fluctuations to continue throughout 2009, even as we plan to experience
overall revenue growth as compared to 2008 levels.

Cost of Goods Sold



|                            |  |                             |       |   |             |   |       |             |  |             |     |  |    |  
|--------------------------- |  | --------------------------- | ----- | - | ----------- | - | ----- | ----------- |  | ----------- | --- |  | -- | -
|                            |  | Three months endedMarch 31, |       |   | Change      |  
|(Dollars in thousands)      |  | 2009                        |       |   | 2008        |   |       | $           |  | %           |    
|                            |  | As Restated                 |       |   | As Restated |   |       | As Restated |  | As Restated |    
|Cost of goods sold          |  | $                           | 5,381 |   |             | $ | 4,537 |             |  | $           | 844 |  | 19 | %
|As a percentage of revenues |  |                             | 72.2  | % |             |   | 98.1  | %           |  |             |     |  |    |  



18



---

##### Table of Contents

Cost of goods sold for the first quarter of 2009 included stock-based compensation expense
of $223,000 as compared to $161,000 for the first quarter of 2008. Cost of goods sold for the first quarter of 2009 include the effects of increases in the overhead applied to our inventory, primarily due to our move into a new facility during 2008.
Overall, cost of goods sold for the first quarter of 2009 benefited from increased production levels and from manufacturing efficiencies as we have reduced the cost of producing our products. We expect that cost of goods sold both as a percentage of
revenue and on a dollar basis will continue to vary from quarter to quarter during 2009 due, among other things, to fluctuations in revenues, average selling prices, the mix of products sold, manufacturing levels and manufacturing yields.

Operating Expenses

Research and Development



|                         |  |                             |       |        |   |       |  |   |     |  |   |  
|------------------------ |  | --------------------------- | ----- | ------ | - | ----- |  | - | --- |  | - | -
|                         |  | Three months endedMarch 31, |       | Change |  
|(Dollars in thousands)   |  | 2009                        |       | 2008   |   | $     |  | % |    
|Research and development |  | $                           | 5,651 |        | $ | 5,214 |  | $ | 437 |  | 8 | %

The change in research and development expenses in the first quarter of 2009 compared
to the first quarter of 2008 was primarily due to the following:



| |  |  | An increase of $0.7 million in outside services, materials and overhead expenses;
| | - |  | ---------------------------------------------------------------------------------



| |  |  | An increase of $0.1 million in stock-based compensation expense due to a larger number of options outstanding, partially offset by the effects of our
lower average stock price; and
| | - |  | ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------



| |  |  | A decrease of $0.4 million in employee-related expenses, including travel expenses, primarily due to a decrease of 11 in average research and
development headcount and the effects of the Companys one-week furlough during the first quarter of 2009.
| | - |  | --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Total research and development expenses in the first quarter of 2009 included $620,000 of stock-based compensation expense compared to $570,000 million in the first quarter of 2008. We expect research and development expenses for the
remainder of 2009 to decrease as compared to 2008 levels as we reduce our employee costs, experience the effects of quarterly one-week furloughs and carefully manage expenses related to our development activities for the electrophysiology market and
exploring certain other potential future applications of our technology.

Selling, General and Administrative



|                                    |  |                            |        |        |   |       |  |   |       |  |    |  
|----------------------------------- |  | -------------------------- | ------ | ------ | - | ----- |  | - | ----- |  | -- | -
|                                    |  | Three monthsendedMarch 31, |        | Change |  
|(Dollars in thousands)              |  | 2009                       |        | 2008   |   | $     |  | % |      
|Selling, general and administrative |  | $                          | 10,111 |        | $ | 8,077 |  | $ | 2,034 |  | 25 | %

Selling, general and administrative expenses increased in the first quarter of 2009
compared to the first quarter of 2008 primarily due to the following:



| |  |  | An increase of $1.6 million in litigation costs associated with our trial against Luna Innovations Incorporated;
| | - |  | ----------------------------------------------------------------------------------------------------------------



| |  |  | $1.0 million in executive severance in the first quarter of 2009, consisting of $0.4 million of severance and $0.6 million of stock-based compensation;
| | - |  | -------------------------------------------------------------------------------------------------------------------------------------------------------



19



---

##### Table of Contents

| |  |  | An increase of $0.3 million in employee-related expenses, exclusive of executive severance, including sales commissions and travel expenses, primarily
due to increased commission expenses in the first quarter of 2009 as compared to 2008, partially offset by a decrease in other employee-related expenses due primarily to a decrease in average general and administrative headcount of 9, partially
offset by an increase in average sales and marketing headcount of 5, and the effects of the Companys one-week furlough during the first quarter of 2009;
| | - |  | ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------



| |  |  | A decrease of $0.1 million in stock-based compensation expense, exclusive of stock-based compensation related to executive severance, due primarily to
the effects of our lower average stock price;
| | - |  | ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------



| |  |  | A decrease of $0.2 million in professional service fees exclusive of Luna litigation costs;
| | - |  | -------------------------------------------------------------------------------------------



| |  |  | An increase of $0.2 million in supplies, equipment and overhead expenses;
| | - |  | -------------------------------------------------------------------------



| |  |  | A decrease of $0.3 million in non-compensation marketing expenses; and
| | - |  | ----------------------------------------------------------------------



| |  |  | A decrease of $0.5 million in lease costs allocated to selling, general and administrative expenses as a result of all lease costs for our new facility
prior to our occupancy in the third quarter of 2008 having been charged to selling, general and administrative expenses.
| | - |  | --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Selling, general and administrative expenses in the first quarter of 2009 included $1.8 million of total stock-based compensation expense compared to $1.3 million in the first quarter of 2008. We expect
our selling, general and administrative expenses for the remainder of 2009 to decrease as compared to 2008 levels as we reduce general and administrative employee costs while we continue to maintain our sales and clinical support groups and
experience the effects of quarterly one-week furloughs.

Interest Income



|                       |  |                             |     |        |   |     |  |   |      |   |  |     |   
|---------------------- |  | --------------------------- | --- | ------ | - | --- |  | - | ---- | - |  | --- | --
|                       |  | Three months endedMarch 31, |     | Change |  
|(Dollars in thousands) |  | 2009                        |     | 2008   |   | $   |  |   | %    |  
|Interest income        |  | $                           | 130 |        | $ | 408 |  | $ | (278 | ) |  | (68 | )%

Interest income decreased in the first quarter of 2009 compared to the first quarter
of 2008 primarily due to decreased average cash, cash equivalents and short-term investments balances in the first quarter of 2009 as compared to 2008, due primarily to the use of cash in operations and to a decrease in interest rates earned on our
outstanding investments. We expect our quarterly interest income to increase in the remainder of 2009 as a result of the proceeds of our equity offering in April 2009.

Interest and Other Expense, net



|                                |  |                             |      |   |        |   |     |   |  |   |      |   |  |     |  
|------------------------------- |  | --------------------------- | ---- | - | ------ | - | --- | - |  | - | ---- | - |  | --- | -
|                                |  | Three months endedMarch 31, |      |   | Change |  
|(Dollars in thousands)          |  | 2009                        |      |   | 2008   |   |     | $ |  |   | %    |  
|Interest and other expense, net |  | $                           | (575 | ) |        | $ | (56 | ) |  | $ | (519 | ) |  | 927 | %

Interest and other expense, net, consists mainly of interest expense and net realized
and unrealized foreign exchange gains and losses. Net foreign exchange losses increased in the first quarter of 2009 as compared to the first quarter of 2008 due primarily to the impact of unfavorable movements in the Euro exchange rate on our
Euro-denominated accounts receivable. Interest expense increased in the first quarter of 2009 as compared to 2008 primarily due to the interest on our term equipment line. We expect our interest expense to increase in the remainder of 2009 over 2008
levels as we have a full year of interest related to the term equipment line.



20



---

##### Table of Contents

Liquidity and Capital Resources

We have incurred losses since our inception in September 2002 and, as of March 31, 2009 we had an accumulated deficit of $181.9 million.
We have financed our operations to date principally through the sale of capital stock, debt financing, interest earned on investments and the sales of our products. Prior to our initial public offering of stock in November 2006, we had received net
proceeds of $61.3 million from the issuance of common and preferred stock and $7.0 million in debt financing. Through our initial public offering in 2006 we received net proceeds of $78.3 million. On April 7, 2008, we sold 3,000,000 shares of
our common stock, resulting in approximately $39.5 million of net proceeds. On April 22, 2009, we sold 11,692,000 shares of our common stock, resulting in approximately $35.1 million of net proceeds, after underwriting discounts and commissions
and estimated offering expenses.

On August 25, 2008, we entered into a $25 million loan and security agreement with
Silicon Valley Bank, consisting of a $15 million term equipment line and a one-year $10 million revolving credit line. We have drawn down approximately $12.5 million against the equipment line under this agreement and, as of March 31, 2009, the
remainder of this line is no longer available to us. The $10 million available under the revolving credit line expires in August 2009. Our current debt with Silicon Valley bank is collateralized by substantially all of our assets, excluding
intellectual property, and is subject to certain covenants, including maintaining the required liquidity, achieving specified EBITDA amounts and fulfilling certain reporting requirements.

Our cash and investment balances are held in a variety of interest bearing instruments, including corporate bonds, commercial paper and
money market funds. Cash in excess of immediate requirements is invested in accordance with our investment policy primarily with a view to liquidity and capital preservation.

Cash flow activity for the three months ended March 31, 2009 and 2008 is summarized as follows:



|                                          |  |                             |        |   |      |   |         |  
|----------------------------------------- |  | --------------------------- | ------ | - | ---- | - | ------- | -
|                                          |  | Three months endedMarch 31, |       
|                                          |  | 2009                        |        |   | 2008 |  
|Cash used in operating activities         |  | $                           | (5,991 | ) |      | $ | (13,614 | )
|Cash provided by investing activities     |  |                             | 3,916  |   |      |   | 1,660   |  
|Cash provided by financing activities     |  |                             | 369    |   |      |   | 150     |  
|                                          |  |                             |        |   |      |   |         |  
|Net decrease in cash and cash equivalents |  | $                           | (1,706 | ) |      | $ | (11,804 | )
|                                          |  |                             |        |   |      |   |         |  

Net Cash Used in Operating Activities

Net cash used in operating activities in the first quarter of 2009 and 2008 primarily reflects the net loss for those periods, partially
offset by non-cash charges such as depreciation and amortization and stock-based compensation. Additionally, net cash used in operating activities for the first quarter of 2009 was positively impacted by accounts receivable collections as we
collected on higher previous period accounts receivable balances than in the same periods last year and the reduction of inventory levels. Conversely, cash flows for the first quarter of 2008 were negatively impacted by increasing accounts
receivable and inventory balances as the Company experienced and prepared for early revenue growth.

Net Cash Provided
by Investing Activities

Net cash provided by investing activities in the first quarter of 2009 and 2008 primarily
relates to the proceeds from and purchases of investments as we manage our investment portfolio to provide interest income and liquidity. Investing activities for the first quarter of 2008 were also negatively impacted by the purchase of property
and equipment as we invested in the build-out of our new facility.



21



---

##### Table of Contents

Net Cash Provided by Financing Activities

Net cash provided by financing activities in the first quarter of 2009 and 2008 was primarily due to proceeds from our employee stock
purchase plan and the exercise of stock options. In the first quarter of 2008, this was partially offset by repayments of long-term debt.

Future Capital Requirements

We are still in the early stages of
commercializing our Sensei system and Artisan catheter and we have not achieved profitability. We recognized our first revenues in 2007 and have not generated net income to date. We have experienced significant fluctuations in quarterly revenues
and, especially in the fourth quarter of 2008 and the first quarter of 2009, we saw many potential customers lengthen their sales cycles and postpone purchase decisions due in large part to general economic and capital market conditions. In an
attempt to reduce our future spending, we reduced our work force in the third quarter of 2008 and again in the first quarter of 2009 and instituted quarterly one-week furloughs for 2009. We anticipate that we will continue to incur substantial net
losses for at least the remainder of 2009 as we continue to commercialize our products, maintain and develop the corporate infrastructure required to manufacture and sell our products at sufficient levels and profit margins and operate as a publicly
traded company as well as continue to develop new products and pursue additional applications for our technology platform. On April 22, 2009, we sold 11,692,000 shares of our common stock, resulting in approximately $35.1 million of net
proceeds, after underwriting discounts and commissions and estimated offering expenses.

We believe our existing cash, cash
equivalents and short-term investment balances and the interest income we earn on these balances in addition to the amounts received from our April 2009 stock offering and available under our revolving credit line and amounts received through the
sale of our products will be sufficient to meet our anticipated cash requirements through at least the next year. However, if our cash flows from operating activities over the next year are significantly less than we expect, we may be required to
adopt additional cost-cutting measures, including additional reductions in our work force, reducing the scope of, delaying or eliminating some or all of our planned research, development and commercialization activities or to license to third
parties the rights to commercialize products or technologies that the Company would otherwise seek to commercialize and we may require additional capital. Any such required additional capital may not be available on reasonable terms, if at all. If
we are unable to obtain additional financing, we may be required to reduce the scope of, delay, or eliminate some or all of, our planned research, development and commercialization activities or to license to third parties the rights to
commercialize products or technologies that we would otherwise seek to commercialize, any of which could materially harm our business.

The timing and exact amounts of our future capital requirements will depend on many factors, including but not limited to the following:



| |  |  | the revenue and margins generated by sales of our current and future products;
| | - |  | ------------------------------------------------------------------------------



| |  |  | our ability to generate revenue in a time of overall economic and capital market uncertainty;
| | - |  | ---------------------------------------------------------------------------------------------



| |  |  | the expenses we incur in manufacturing, marketing and selling our products, developing new products and operating our company;
| | - |  | ------------------------------------------------------------------------------------------------------------------------------



| |  |  | our ability to achieve manufacturing cost reductions as we scale the production of our products;
| | - |  | ------------------------------------------------------------------------------------------------



| |  |  | our ability to achieve and maintain operating cost reductions;
| | - |  | --------------------------------------------------------------



| |  |  | the success of our research and development efforts;
| | - |  | ----------------------------------------------------



| |  |  | the rate of progress and cost of our clinical trials and other development activities;
| | - |  | --------------------------------------------------------------------------------------



| |  |  | the cost and timing of future regulatory actions;
| | - |  | -------------------------------------------------



| |  |  | our ability to maintain compliance with debt covenants;
| | - |  | -------------------------------------------------------



22



---

##### Table of Contents

| |  |  | the costs of filing, prosecuting, defending and enforcing any patent claims and other intellectual property or other legal rights, or participating in
litigation-related activities;
| | - |  | -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------



| |  |  | the emergence of competing or complementary technological developments;
| | - |  | -----------------------------------------------------------------------



| |  |  | the terms and timing of any collaborative, licensing or other arrangements that we may establish; and
| | - |  | -----------------------------------------------------------------------------------------------------



| |  |  | the acquisition of businesses, products and technologies.
| | - |  | ---------------------------------------------------------

We cannot guarantee that future equity or debt financing or credit facilities will be available in amounts or on terms acceptable to us, if
at all. This could leave us without adequate financial resources to fund our operations as presently conducted or as we plan to conduct them in the future.

Contractual Obligations

The following table summarizes our outstanding
contractual obligations as of March 31, 2009:



|                              |  |                                       |        |                 |   |           |  |           |        |                  |   |       |  |   |      
|----------------------------- |  | ------------------------------------- | ------ | --------------- | - | --------- |  | --------- | ------ | ---------------- | - | ----- |  | - | -----
|                              |  | Payments Due by Period (in thousands)
|Contractual Obligations       |  | Total                                 |        | Less than1
Year |   | 1-3 Years |  | 3-5 years |        | More than5
Years
|Operating lease  real estate |  | $                                     | 10,400 |                 | $ | 1,359     |  | $         | 3,527  |                  | $ | 3,731 |  | $ | 1,783
|Debt                          |  |                                       | 14,644 |                 |   | 2,978     |  |           | 7,940  |                  |   | 3,726 |  |   |     
|                              |  |                                       |        |                 |   |           |  |           |        |                  |   |       |  |   |      
|Total                         |  | $                                     | 25,044 |                 | $ | 4,337     |  | $         | 11,467 |                  | $ | 7,457 |  | $ | 1,783
|                              |  |                                       |        |                 |   |           |  |           |        |                  |   |       |  |   |      

The table above reflects only payment obligations that are fixed and determinable.
Our commitments for operating leases relate principally to the lease for our corporate headquarters in Mountain View, California. Current future debt payments relate to principal and interest payments related to the $12.5 million we have borrowed
under our term equipment line with Silicon Valley Bank. Additionally, we have minimum royalty obligations of $100,000 per year under a license agreement with Mitsubishi Electric Research Laboratories, Inc. which reduces to $55,000 per year if the
license becomes non-exclusive. The royalty obligation expires in 2018. We may also have minimum royalty obligations under the terms of our cross license agreement with Intuitive Surgical, Inc. Our agreement to acquire AorTx includes possible future
payments of up to $30.0 million payable upon achievement of regulatory clearances and revenue and partnering milestones. Such future payments are to be made 50% in cash and 50% in shares of our common stock. Pursuant to the terms of the AorTx
acquisition, we have given notice to the former AorTx stockholders of our election to license the acquired AorTx technologies back to an entity formed by the former AorTx stockholders rather than be required to make a $5 million payment to the
former AorTx stockholders on May 15, 2009.

Recent Accounting Pronouncements

There are a number of new accounting pronouncements and interpretations that will impact our financial statements and disclosures (see Note 2
to our condensed consolidated financial statements under the caption Recent Accounting Pronouncements). We have not experienced, nor do we expect to experience a material impact on our results of operations, financial position or cash
flows upon adoption of any of those pronouncements or interpretations.

ITEM 3. QUANTITATIVE AND QUALITATIVE
DISCLOSURES ABOUT MARKET RISK (Restated)

In the normal course of business, our financial position is subject to a variety
of risks, including market risk associated with interest rate movements and foreign currency exchange risk. We regularly assess these risks and have established policies and business practices to protect against these and other exposures. As a
result, we do not anticipate material potential losses in these areas.



23



---

##### Table of Contents

The primary objective for our investment activities is to preserve principal while
maximizing yields without significantly increasing risk. This is accomplished by investing in widely diversified short-term investments, consisting primarily of investment grade securities. As of March 31, 2009, the fair value of our cash, cash
equivalents and short-term investments was approximately $29.3 million, the majority of which will mature in one year or less. A hypothetical 50 basis point increase in interest rates would not result in a material decrease or increase in the fair
value of our available-for-sale securities. We have no investments denominated in foreign country currencies and therefore our investments are not subject to foreign currency exchange risk.

A portion of our operations consist of sales activities outside of the United States and, as such, we have foreign currency exposure to
non-United States dollar revenues and accounts receivable. Currently, we sell our products mainly in United States dollars, Euros and Great Britain Pounds although we may in the future transact business in other currencies. Future fluctuations in
the exchange rates of these currencies may impact our revenues. In the past, we have not hedged our exposures to foreign currencies or entered into any other derivative instruments and we have no current plans to do so. In the quarter ended
March 31, 2009, sales denominated in foreign currencies were approximately 13% of total revenue. A hypothetical 10% increase in the United States dollar exchange rate used would have resulted in a decrease of approximately $95,000 in revenues
for the first quarter of 2009.

ITEM 4. CONTROLS AND PROCEDURES (Restated)

Evaluation of Disclosure Controls and Procedures

Our senior management is responsible for establishing and maintaining a system of disclosure controls and procedures (as defined in Rule 13a-15 and 15d-15 under the Securities Exchange Act of 1934 (the
Exchange Act)) designed to ensure that information required to be disclosed by us in the reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the
Securities and Exchange Commissions rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by an issuer in the reports that it files
or submits under the Exchange Act is accumulated and communicated to the issuers management, including its principal executive officer or officers and principal financial officer or officers, or persons performing similar functions, as
appropriate to allow timely decisions regarding required disclosure.

In our Quarterly Report on Form 10-Q for the quarter
ended March 31, 2009, originally filed on May 8, 2009, our management, with the participation of our Chief Executive Officer and Chief Financial Officer, concluded that our disclosure controls and procedures were effective as of
March 31, 2009. In connection with our decision to restate our financial statements, as more fully described in Note 3 to the financial statements of this Form 10-Q/A, our management, including our Chief Executive Officer and Chief Financial
Officer, performed a reevaluation and concluded that our disclosure controls and procedures were not effective as of March 31, 2009 as a result of the material weaknesses in our internal control over financial reporting as discussed below.

Material Weaknesses in Internal Control over Financial Reporting

A material weakness is a deficiency, or a combination of deficiencies, in internal control over financial reporting such that there is a
reasonable possibility that a material misstatement of the Companys annual or interim financial statements will not be prevented or detected on a timely basis.

In connection with the restatement described in Note 3 to the financial statements, we reevaluated our internal control over financial reporting and have identified the following material weaknesses:

1.    Control Environment. We did not maintain an effective control environment, which is the
foundation upon which all other components of internal controls are based. Specifically:



| |  |  | Our commercial operations leadership did not consistently support the importance of strict adherence to our revenue recognition policy and to GAAP and
did not take sufficient steps to ensure good faith compliance with revenue recognition policies throughout our sales, clinical and field service departments. As a result, information related to certain revenue transactions was not communicated to
accounting personnel to appropriately consider the financial reporting implications of such transactions.
| | - |  | -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------



| |  |  | We did not maintain sufficient safeguards to provide reasonable assurance that controls could not be circumvented or overridden by commercial
operations management or to prevent or detect possible misconduct by members of our commercial operations organization with respect to certain revenue transactions. Our commercial operations organization was structured such that the sales, clinical
and field service departments all reported to the executive in charge of our commercial operations, leading to a conflict of oversight and incentives, such as the desire to meet quarterly sales goals.
| | - |  | ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------



24



---

##### Table of Contents

| |  |  | We did not maintain effective procedures for communicating to all relevant personnel our accounting policies, the importance of consistent application
of our accounting policies, and essential data required to properly apply GAAP to our transactions.
| | - |  | ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------



| |  |  | Additionally, we did not effectively communicate the process of reporting unusual or uncertain circumstances. As a result, we did not detect
deficiencies in compliance with our accounting policies on a timely basis.
| | - |  | -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

This material weakness led to errors and
irregularities that in turn resulted in errors in the preparation of our financial statements. This material weakness also contributed to the existence of the material weakness described in item 2 below.

2.    Revenue recognition process.We did not maintain effective controls related to the process for ensuring
completeness and accuracy of our accounting for revenue to provide reasonable assurance that all significant details of agreements with our distributors and customers were provided to those making revenue recognition decisions and that all
appropriate personnel received sufficient training on revenue recognition.



| |  |  | Certain employees were able to withhold information from accounting personnel or falsify documentation related to certain revenue transactions without
discovery, which resulted in improper recognition of revenue in the period.
| | - |  | ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------



| |  |  | Accounting personnel were not provided the necessary information to determine the financial reporting consequences of certain revenue transactions.
Specifically, this led to incomplete information regarding temporary installations, unfulfilled training obligations, the inability of distributors to independently install systems and train end users, and undisclosed side arrangements.
| | - |  | ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

These material weaknesses resulted in material errors and the restatement of the our annual statements for
2007, annual and interim financial statements for 2008 and interim financial statements for the first and second quarters of 2009, impacting revenue, cost of goods sold, deferred cost of goods sold, and deferred revenue accounts. Additionally, these
material weaknesses could result in further misstatements of these accounts that would result in a material misstatement of our financial statements that would not be prevented or detected on a timely basis.

Notwithstanding the material weaknesses described above, we concluded that the interim financial statements included in this Form 10-Q/A
fairly present, in all material respects, our financial condition, results of operations and cash flows as of and for the periods presented in accordance with GAAP.

Changes in Internal Control Over Financial Reporting

As described under
the paragraph entitled Material Weaknesses in Internal Control over Financial Reporting, there were changes in internal control over financial reporting during the quarter ended March 31, 2009 that have materially affected, or are reasonably
likely to materially affect, our internal control over financial reporting.

Managements Plan for Remediation

Beginning in October 2009, our management began to design and implement certain remediation measures to address the above-described material
weaknesses and enhance our system of internal control over financial reporting. Management believes the remediation measures described below will remediate the identified control deficiencies and strengthen our internal control over financial
reporting. As management continues to evaluate and work to enhance our internal control over financial reporting, it may be determined that additional measures must be taken to address control deficiencies or it may be determined that we need to
modify or otherwise adjust the remediation measures described below.

The remediation efforts outlined below are intended both
to address the identified material weaknesses and to enhance our overall financial control environment.

Control
Environment and Organizational Structure.Our plan is to create and communicate an effective culture and tone throughout the Companys commercial operations organization in the following ways:



| |  |  | Certain employees have been terminated and other employees will be disciplined for actions relating to this restatement.
| | - |  | ------------------------------------------------------------------------------------------------------------------------



| |  |  | We will improve the annual ethics training for all sales, clinical and field service employees to enhance their understanding of critical accounting
and ethics policies.
| | - |  | -------------------------------------------------------------------------------------------------------------------------------------------------------------------------



| |  |  | We will reorganize our sales, clinical and field service teams such that they will no longer report to the same vice president to ensure that each team
has the proper oversight and incentives.
| | - |  | ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------



25



---

##### Table of Contents

Revenue Recognition Process. We will enhance our internal controls related to
the revenue recognition process and training in the following ways:



| |  |  | We will increase management oversight by expanding our processes to include more rigorous representations made by sales, clinical and field service
personnel and more detailed documentation regarding elements required for revenue recognition and timely accountability for details underlying elements of revenue recognition.
| | - |  | -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------



| |  |  | We will improve communications between accounting personnel responsible for revenue recognition and sales, clinical and field service personnel
responsible for the execution of the work on those transactions and will institute quarterly meetings involving accounting and sales, clinical and field service personnel involved in each system sale during the quarter.
| | - |  | ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------



| |  |  | We will improve the annual ethics training for all sales, clinical and field service employees to enhance their understanding of critical accounting
and ethics policies.
| | - |  | -------------------------------------------------------------------------------------------------------------------------------------------------------------------------



| |  |  | We will expand our revenue recognition training to include clinical and field service employees to promote their understanding of and appreciation for
our revenue recognition policy and process.
| | - |  | --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------



| |  |  | We will improve our existing revenue recognition training to include a more detailed description of our revenue recognition process.
| | - |  | ------------------------------------------------------------------------------------------------------------------------------------

ITEM 4T. CONTROLS AND PROCEDURES

Not applicable.

PART II. OTHER INFORMATION

ITEM 1. LEGAL PROCEEDINGS

On June 22, 2007, we filed suit in Santa Clara Superior Court against Luna Innovations Incorporated, or Luna, alleging that Luna has,
among other things, breached a 2006-2007 development and intellectual property agreement with us that we believe establishes our ownership of all intellectual property in medical robotics developed by the parties during performance of the agreement,
misappropriated our trade secrets and has revealed our confidential information to other companies who might improperly benefit from it. On April 21, 2009, after an approximately four week trial, a jury awarded us approximately $36.3 million in
damages, finding in our favor on our breach of contract, breach of the covenant of good faith and fair dealing, and misappropriation of trade secrets claims against Luna. The jury did not find in our favor on our fraud claims against Luna, but did
find that Lunas misappropriation was willful or malicious. The verdict and recovery of damages is subject to customary post-trial motions and appeals, as well as collection risks.

ITEM 1A. RISK FACTORS

Risks Related to Our Business

We are a company with a limited history of operations, which makes our future operating results difficult to predict.

We are a medical device company with a limited operating history and first recognized revenues in the second quarter
of 2007. Prior to the second quarter of 2007, we were a development stage company. We have been engaged in research and product development since our inception in late 2002. Our Sensei Robotic Catheter System, or Sensei system, and our corresponding
disposable Artisan catheter received



26



---

##### Table of Contents

FDA clearance in May 2007 for commercialization to facilitate manipulation, positioning and control of certain mapping catheters during electrophysiology procedures. We also received the CE Mark
in Europe for our Sensei system in September 2006 and for our Artisan catheter in May 2007. As of March 31, 2009, we have also received regulatory approvals in Russia and Australia. The future success of our business will depend on our ability
to manufacture and assemble our products in sufficient quantities in accordance with applicable regulatory requirements and at lower costs, increase product sales and successfully introduce new products, all of which we may be unable to do. We have
a limited history of operations upon which you can evaluate our business and our operating expenses have increased significantly. Our lack of a significant operating history also limits your ability to make a comparative evaluation of us, our
products and our prospects. If we are unable to successfully operate our business, our business and financial condition will be harmed.

Credit, financial market and general economic conditions could delay or prevent potential customers from purchasing our products, which would adversely affect our sales, financial condition and
results of operation.

The sale of a Sensei system often represents a significant capital purchase for our customers
and many customers finance their purchase of a Sensei system through a credit facility or other financing. If prospective customers that need to finance their capital purchases are not able to access the credit or capital markets on terms that they
consider acceptable, they may decide to postpone or cancel a potential purchase of a Sensei system. Also, even customers with sufficient financial resources to make such purchases without resorting to the credit and capital markets may be less
likely to make capital purchases during periods when they view the overall economic conditions unfavorably or with uncertainty. Financial market conditions in the U.S. and the European Union since the fourth quarter of 2008, including especially the
credit and capital markets, have been extremely volatile and uncertain. As a result, many potential customers delayed making a decision to purchase a Sensei system, which has significantly impacted our sales, financial condition and results of
operations. Financial market conditions are likely to continue to be volatile into the future. We believe that the macroeconomic environment and the deterioration in confidence and spending have impacted and will continue to impact potential
customers and their decisions to purchase our products into the foreseeable future. We cannot predict the timing, strength or duration of any economic slowdown or subsequent recovery, whether worldwide, regional or specific to our industry, nor the
extent of its potential impact on our future sales, financial condition and results of operations.

We have limited
sales, marketing and distribution experience and capabilities, which could impair our ability to achieve profitability.

In the second quarter of 2007, we received clearance to market, sell and distribute our products in the United States and Europe. We had no prior experience as a company in undertaking these efforts. In the United States, we market our
products through a direct sales force of regional sales employees, supported by clinical account managers who provide training, clinical support and other services to our customers. Our direct sales force competes against the experienced and
well-funded sales organizations of our competitors. Our revenues will depend largely on the effectiveness of our sales force. We face significant challenges and risks related to our direct sales force and the marketing of our products, including,
among others:



| |  |  | the ability of sales personnel to obtain access to or persuade adequate numbers of hospitals to purchase our products or physicians to use our
products;
| | - |  | --------------------------------------------------------------------------------------------------------------------------------------------------------



| |  |  | our ability to retain, properly motivate, recruit and train adequate numbers of qualified sales and marketing personnel;
| | - |  | ------------------------------------------------------------------------------------------------------------------------



| |  |  | the costs associated with an independent sales and marketing organization, hiring, maintaining and expanding an independent sales and marketing
organization; and
| | - |  | -----------------------------------------------------------------------------------------------------------------------------------------------------------------



| |  |  | assuring compliance with government scrutiny and labeling restrictions with respect to promotional activities in the healthcare industry.
| | - |  | -----------------------------------------------------------------------------------------------------------------------------------------



27



---

##### Table of Contents

Outside the United States, primarily in the European Union, we are establishing a
combination of a direct sales force and distributors to market, sell and support our products. If we fail to select appropriate distributors or effectively use our distributors or sales personnel and coordinate our efforts for distribution of our
products in the European Union or if their and our sales and marketing strategies are not effective in generating sales of our products, our revenues would be adversely affected and we may never become profitable.

We have limited experience in manufacturing and assembling our products and may encounter problems at our manufacturing facilities or
otherwise experience manufacturing delays that could result in lost revenue or diminishing margins.

We do not have
significant experience in manufacturing, assembling or testing our products on a commercial scale. In addition, for our Sensei system, we subcontract the manufacturing of major components and complete the final assembly and testing of those
components in-house. We face challenges in order to produce our Sensei system and disposable Artisan catheters in quantities sufficient to meet anticipated market demand, to efficiently utilize our new manufacturing facility and to achieve planned
manufacturing cost reductions. These challenges include equipment design and automation, material procurement, low or variable production yields on Artisan catheters and quality control and assurance. The costs resulting from these challenges and
our relocation to a larger facility have had and will continue to have a significant impact on our gross margins and may result in significant fluctuations of gross margins from quarter to quarter. We may not successfully complete required increases
in manufacturing capacity or planned improvements in manufacturing efficiency on a timely basis or at all. For example, as we were increasing our manufacturing capacity for Artisan catheters, we shipped a limited number in late 2007 and early 2008
that were later identified as having a potential leak. Although no patient is known or suspected to have experienced any consequences associated with this possible leak nor has it significantly impacted our business, these events were reported to
the FDA in accordance with applicable regulations and we subsequently initiated a voluntary recall of the affected devices. The recall was closed in June 2008. We may encounter other manufacturing issues that result in our being unable to meet the
expected demand for our Sensei system or Artisan catheters, maintain control over our expenses or otherwise successfully increase our manufacturing capabilities. If we are unable to satisfy demand for our Sensei system or Artisan catheters, our
ability to generate revenue could be impaired and hospitals may instead purchase, or physicians may use, our competitors products. Since our Sensei system requires the use of disposable Artisan catheters, our failure to meet demand for Artisan
catheters from hospitals that have purchased our Sensei system could adversely affect the market acceptance of our products and damage our commercial reputation.

In addition, all of our operations are conducted at our facilities leased in Mountain View, California. We could encounter problems at these facilities, which could delay or prevent us from manufacturing,
assembling or testing our products or maintaining our manufacturing capabilities or otherwise conducting operations.

Our reliance on third-party manufacturers and on suppliers, and in one case, a single-source supplier, could harm our ability to meet demand for our products in a timely manner or within budget, and could cause harm to our business
and financial condition.

We depend on third-party manufacturers to produce most of the components of our Sensei
system and other products, and have not entered into formal agreements with several of these third parties. We also depend on various third-party suppliers for various components we use in our Sensei systems and for our Artisan catheters and
sheaths. For example, Force Dimension Sàrl, a single-source supplier, manufactures customized motion controllers that are a part of our Sensei system. We also obtain the motors for our Sensei system from a single supplier, Maxon Motor AG,
from whom we purchase on a purchase order basis, and we generally do not maintain large volumes of inventory. Additionally, in October 2007, we entered into a purchase agreement with Plexus Services Corp., or Plexus, under which Plexus will
manufacture certain components for us in quantities determined by a non-binding forecast and by purchase orders.



28



---

##### Table of Contents

Our reliance on third parties involves a number of risks, including, among other things, the
risk that:



| |  |  | suppliers may fail to comply with regulatory requirements or make errors in manufacturing components that could negatively affect the efficacy or
safety of our products or cause delays in or prevent shipments of our products;
| | - |  | ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------



| |  |  | we may not be able to respond to unanticipated changes and increases in customer orders;
| | - |  | ----------------------------------------------------------------------------------------



| |  |  | we may be subject to price fluctuations due to a lack of long-term supply arrangements for key components with our suppliers;
| | - |  | -----------------------------------------------------------------------------------------------------------------------------



| |  |  | we may lose access to critical services and components, resulting in an interruption in the manufacture, assembly and shipment of our systems and other
products;
| | - |  | -----------------------------------------------------------------------------------------------------------------------------------------------------------------



| |  |  | our suppliers manufacture products for a range of customers, and fluctuations in demand for products these suppliers manufacture for others may affect
their ability to deliver components to us in a timely manner;
| | - |  | --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------



| |  |  | our suppliers may wish to discontinue supplying goods or services to us;
| | - |  | ------------------------------------------------------------------------



| |  |  | we may not be able to find new or alternative components for our use or reconfigure our system and manufacturing processes in a timely manner if the
components necessary for our system become unavailable; and
| | - |  | ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------



| |  |  | our suppliers may encounter financial hardships unrelated to our demand for components, which could inhibit their ability to fulfill our orders and
meet our requirements.
| | - |  | --------------------------------------------------------------------------------------------------------------------------------------------------------------------------

If any of these risks materialize, it could significantly increase our costs and
impact our ability to meet demand for our products.

In addition, if these manufacturers or suppliers stop providing us with
the components or services necessary for the operation of our business, we may not be able to identify alternative sources in a timely fashion. Any transition to alternative manufacturers or suppliers or a decision to discontinue our relationship
with a current manufacturer or supplier could result in operational problems, increased expenses or write-down of capitalized assets that would adversely affect gross margins and could delay the shipment of, or limit our ability to provide, our
products. We cannot assure you that we would be able to enter into agreements with new manufacturers or suppliers on commercially reasonable terms or at all. Additionally, obtaining components from a new supplier may require qualification of a new
supplier in the form of a new or supplemental filing with applicable regulatory authorities and clearance or approval of the filing before we could resume product sales. Any disruptions in product supply may harm our ability to generate revenues,
lead to customer dissatisfaction, damage our reputation and result in additional costs or cancellation of orders by our customers. We currently purchase a number of the components for our Sensei system in foreign jurisdictions. Any event causing a
disruption of imports, including the imposition of import restrictions, could adversely affect our business and our financial condition.

If we fail to maintain necessary FDA clearances and CE marks for our medical device products, or if future clearances are delayed, we will be unable to commercially distribute and market our
products.

The process of seeking regulatory clearance or approval to market a medical device is expensive and
time-consuming and clearance or approval is never guaranteed and, even if granted, clearance or approval may be suspended or revoked. In May 2007, we received FDA clearance in the United States to commercialize our Sensei system and Artisan
catheters only to facilitate manipulation, positioning and control, for collecting electrophysiological data within the heart atria with electro-anatomic mapping and recording systems. Because the FDA has determined that there is a reasonable
likelihood that our products could be used by physicians for uses not encompassed by the scope of the present FDA clearance and that such uses may cause harm, we are required to label our products to state that their safety and effectiveness for use
with cardiac ablation catheters in the treatment of cardiac arrhythmias including atrial fibrillation have not been established. Accordingly, the scope of the current label may be an obstacle to our ability to successfully market and sell our
products in the United States to a broader group of potential customers. We will be required to seek a separate 510(k) clearance or PMA to market our Sensei system for uses other than those currently cleared by the FDA. We cannot assure you that the
FDA would not impose a more



29



---

##### Table of Contents

burdensome level of premarket review on other intended uses or modifications to approved products. We may seek future clearances or approvals of our Sensei system for other indications, including
atrial fibrillation or other cardiac ablation procedures but there can be no assurance as to the timing or potential for success of those efforts if undertaken. We received the CE Mark in Europe for our Sensei system in September 2006 and for our
Artisan catheters in May 2007, but we may be required to seek separate clearances from the European Union in order to market our Sensei system for any additional uses. Such approval may be difficult and costly to achieve, or may not be granted at
all.

Seeking to obtain future clearances or approvals from the FDA and other regulatory authorities could result in
unexpected and significant costs for us and consume managements time and other resources. The FDA or other regulatory authorities could ask us to supplement our submissions, collect non-clinical data, conduct clinical trials or engage in other
time-consuming or costly actions, or it could simply deny our applications. Seeking new approvals could also result in the FDA or other regulatory authorities reviewing prior submissions and modifying or revoking prior approvals. In addition,
clearance or approval could be revoked or other restrictions imposed if post-market data demonstrates safety issues or lack of effectiveness. We cannot predict with certainty how, or when, the FDA or other regulatory authorities will act. If we are
unable to maintain our regulatory clearances and obtain future clearance, our financial condition and cash flow may be adversely affected, and our ability to grow domestically and internationally may be limited.

If physicians and hospitals do not believe that our products are a safe and effective alternative to existing technologies used in
atrial fibrillation and other cardiac ablation procedures, they may choose not to use our Sensei system.

We believe
that physicians will not use, and hospitals will not purchase, our products unless they determine that our Sensei system provides a safe and effective alternative to existing treatments. Since we have received FDA clearance to market our Sensei
system and disposable Artisan catheters only for guiding catheters to map the heart anatomy, we will not be able to label or promote these products, or train physicians, for use in guiding catheters for cardiac ablation procedures until such
clearance or approval is obtained. Currently, there is only limited clinical data on our Sensei system with which to assess its safety and efficacy in any procedure, including atrial fibrillation and other cardiac ablation procedures. Studies are
currently under way outside the United States comparing the safety, usability and success of the treatment of atrial fibrillation with our Sensei system to manual techniques. If these studies, or other clinical studies performed by us or others, or
clinical experience indicate that procedures with our Sensei system or the type of procedures that can be performed with the Sensei system are not effective or safe for such uses, physicians may choose not to use our Sensei system. Reluctance by
physicians to use our Sensei system or to perform procedures enabled by the Sensei system would harm sales. Further, unsatisfactory patient outcomes or patient injury could cause negative publicity for our products, particularly in the early phases
of product introduction. In addition, physicians may be slow to adopt our products if they perceive liability risks arising from the use of these new products. It is also possible that as our products become more widely used, latent or other defects
could be identified, creating negative publicity and liability problems for us, thereby adversely affecting demand for our products. If physicians do not use our products in cardiac ablation procedures, we likely will not become profitable and our
business will be harmed.

In addition, our research and development efforts and our marketing strategy depend heavily on
obtaining support and collaboration from highly regarded physicians at leading hospitals. If we are unable to gain or maintain such support and collaboration, our ability to market our Sensei system and, as a result, our business and results of
operations, could be harmed.

We expect to derive substantially all of our revenues from sales of our Sensei system and
Artisan catheters. If hospitals do not purchase our system, we may not generate sufficient revenues to continue our operations.

Our initial commercial offering consists primarily of two products, our Sensei system and our corresponding disposable Artisan catheters. The Sensei system has recently been supplemented by an optional
CoHesion Module. In order for us to achieve sales, hospitals must purchase our Sensei system and Artisan catheters. Our Sensei system is a novel device, and hospitals are traditionally slow to adopt new



30



---

##### Table of Contents

products and treatment practices. In addition, our Sensei system is an expensive capital equipment purchase, representing a significant portion of an electrophysiology laboratorys annual
budget. In addition, because it has only recently been commercially introduced, our Sensei system has limited product and brand recognition. Furthermore, particularly in this period of economic volatility and uncertainty, we do not believe hospitals
will purchase our products unless the physicians at those hospitals express a strong desire to use our products and we cannot predict whether or not they will do so. If hospitals do not widely adopt our Sensei system, or if they decide that it is
too expensive, we may never achieve significant revenue or become profitable. Such a failure to adequately sell our Sensei system would have a materially detrimental impact on our business, results of operations and financial condition.

We have incurred substantial losses since inception and anticipate that we will incur continued losses for the foreseeable future
and we may not be able to raise additional financing to fund future losses.

We have experienced substantial net
losses since our inception in late 2002. At March 31, 2009, we had an accumulated deficit of $181.9 million. We have funded our operations to date principally from the sale of our securities and through issuance of debt. In 2008, we both issued
equity and entered into a new debt facility; however, we may at any time sell additional securities resulting in further dilution to existing stockholders and we may at any time incur additional indebtedness. Also, the recent turmoil in the global
financial and credit markets may limit our ability to raise additional funds. We cannot guarantee that future equity or debt financing will be available in amounts or on terms acceptable to us, if at all. Further, even if financing becomes
available, the cost to us may be significantly higher than in the past. We will continue to face significant challenges if conditions in the financial markets do not improve or continue to worsen. In particular, our ability to access the capital
markets and raise funds required for our operations may be severely restricted at a time when we would like, or need, to do so, which could have an adverse effect on our ability to meet our current and future funding requirements and on our
flexibility to react to changing economic and business conditions. This could leave us without adequate financial resources to fund our operations as presently conducted or as we plan to conduct them in the future.

We expect to incur substantial additional net losses for at least the next year as we continue our manufacturing, marketing and sales
operations to commercialize our products and seek additional regulatory clearances. We expect our research and development and general and administrative expenses to decrease in 2009 from 2008 levels, but to remain significant as we maintain the
infrastructure necessary to support operating as a public company, develop our intellectual property portfolio and incur other intellectual property related legal expenses, including litigation expenses. Because we may not be successful in
significantly increasing sales of our products, the extent of our future losses and the timing of profitability are highly uncertain, and we may never achieve profitable operations. If we require more time than we expect to generate significant
revenue and achieve profitability, we may not be able to continue our operations. Even if we achieve significant revenues, we may never become profitable or we may choose to pursue a strategy of increasing market penetration and presence at the
expense of profitability.

We may incur significant liability if it is determined that we are promoting off-label use of
our products in violation of federal and state regulations in the United States or elsewhere.

We have received FDA
clearance of our Sensei system and Artisan catheters only to facilitate manipulation, positioning and control for collecting electrophysiological data within the heart atria with electro-anatomic mapping and recording systems, which is a critical
step in the identification of the heart tissue generating abnormal heart rhythms that may require ablation or other treatment. Because the FDA has determined that there is a reasonable likelihood that physicians may choose to use our products
off-label, and that harm may result, we are required to label our products to state that their safety and effectiveness for use with cardiac ablation catheters in the treatment of cardiac arrhythmias including atrial fibrillation have not been
established. We may subsequently seek regulatory clearance for use of our Sensei system for use with other catheters, including ablation catheters, or for a variety of other interventional procedures in electrophysiology, including atrial
fibrillation and other cardiovascular procedures. Our business and future growth will depend primarily on the use of our Sensei system in the treatment of atrial fibrillation and other cardiovascular procedures, for which we do not yet, and may
never, have FDA clearance or approval.



31



---

##### Table of Contents

Unless and until we receive regulatory clearance or approval for use of our Sensei system
with ablation catheters or in these procedures, uses in these procedures will be considered off-label uses of our Sensei system. Under the Federal Food, Drug, and Cosmetic Act and other similar laws, we are prohibited from labeling or promoting our
products, or training physicians, for such off-label uses. This prohibition means that the FDA could deem it unlawful for us to make claims about the safety or effectiveness of our Sensei system for use with ablation catheters and in cardiac
ablation procedures and that we may not proactively discuss or provide information or training on the use of our product in cardiac ablation procedures or use with unapproved catheters, with very limited exceptions. We presently believe that to
date, all of the procedures in which our products have been used in the United States have included off-label uses such as cardiac ablation, for which our Sensei system and Artisan catheters have not been cleared by the FDA.

The FDA and other regulatory agencies actively enforce regulations prohibiting promotion of off-label uses and the promotion of products for
which marketing clearance or approval has not been obtained. Moreover, scrutiny of such practices by the FDA and other federal agencies has recently increased. Promotional activities for FDA regulated products of other companies have been the
subject of enforcement action brought under healthcare reimbursement laws and consumer protection statutes. A company that is found to have improperly promoted off-label uses may be subject to significant liability, including civil and
administrative remedies under the Federal False Claims Act and various other federal and state laws, as well as criminal sanctions.

Due to these legal constraints, our sales and marketing efforts focus on the general technical attributes and benefits of our Sensei system and the use of this device to guide two specific catheters for heart mapping. If we are perceived
not to be in compliance with all of the restrictions limiting the promotion of our products for off-label use, we could be subject to various enforcement measures, including investigations, administrative proceedings and federal and state court
litigation, which would likely be costly to defend and harmful to our business. If the FDA or another governmental authority ultimately concludes we are not in compliance with such restrictions, we could be subject to significant liability,
including civil and administrative remedies, injunctions against sales for off-label uses, significant monetary and punitive penalties and criminal sanctions, any or all of which would be harmful to our business and in certain instances may cause us
to have to cease operations.

The training required for physicians to use our Sensei system could reduce the market
acceptance of our system and reduce our revenue.

It is critical to the success of our sales efforts to ensure that
there are a sufficient number of physicians familiar with, trained on and proficient in the use of our Sensei system. Convincing physicians to dedicate the time and energy necessary for adequate training in the use of our system is challenging, and
we cannot assure you that we will be successful in these efforts.

It is our policy to only train physicians to insert,
navigate, map and remove catheters using our Sensei system. Physicians must obtain training elsewhere to learn how to ablate cardiac tissue to treat atrial fibrillation, which is an off-label procedure. This training may be provided by third
parties, such as hospitals and universities and through independent peer-to-peer training among doctors. We cannot assure you that a sufficient number of physicians will become aware of training programs or that physicians will dedicate the time,
funds and energy necessary for adequate training in the use of our system. Additionally, we will have no control over the quality of these training programs. If physicians are not properly trained, they may misuse or ineffectively use our products.
This may result in unsatisfactory outcomes, patient injury, negative publicity or lawsuits against us, any of which could negatively affect our reputation and sales of our products. Furthermore, our inability to educate and train physicians to use
our Sensei system for atrial fibrillation or other cardiac ablation procedures may lead to inadequate demand for our products and have a material adverse impact on our business, financial condition and results of operation.



32



---

##### Table of Contents

Training in the use of our products is regulated by the FDA. Our physician training and the
training provided by third parties typically includes facilitating an observation of a Sensei case by the trainee physician. We monitor our training to ensure that off-label use is not promoted or enabled. However, from time to time, we may sponsor
third party training. There is a risk that independent peer-to-peer interaction between physicians and other third party training may include discussion or observation of off-label procedures because most procedures performed to date using the
Sensei system involve both mapping and cardiac ablation. If any such activities are attributed to us, the FDA or other governmental entities could conclude that we have engaged in off-label promotion of our products, which could subject us to
significant liability.

Because our markets are highly competitive, customers may choose to purchase our
competitors products, which would result in reduced revenue and harm our financial results.

Our Sensei system is a new technology and must compete with established manual interventional methods and methods of our competitors, such as Stereotaxis, Inc., in remote navigation. Conventional manual methods are widely accepted in the
medical community, have a long history of use and do not require the purchase of additional, expensive capital equipment. The Stereotaxis Niobe® system, which has been in the market since 2003, four years earlier than our Sensei system, has been adopted by a number of leading clinicians. In addition, many of
the medical conditions that can be treated using our products can also be treated with existing drugs or other medical devices and procedures. Many of these alternative treatments are widely accepted in the medical community and have a long history
of use.

We also face competition from companies that are developing drugs or other medical devices or procedures to treat the
conditions for which our products are intended. The medical device and pharmaceutical industries make significant investments in research and development and innovation is rapid and continuous. If new products or technologies emerge that provide the
same or superior benefits as our products at equal or lesser cost, they could render our products obsolete or unmarketable. We cannot be certain that physicians will use our products to replace or supplement established treatments or that our
products will be competitive with current or future products and technologies.

Most of our competitors enjoy several
competitive advantages over us, including:



| |  |  | significantly greater name recognition;
| | - |  | ---------------------------------------



| |  |  | longer operating histories;
| | - |  | ---------------------------



| |  |  | established relations with healthcare professionals, customers and third-party payors;
| | - |  | --------------------------------------------------------------------------------------



| |  |  | established distribution networks;
| | - |  | ----------------------------------



| |  |  | additional lines of products, and the ability to offer rebates or bundle products to offer higher discounts or incentives to gain a competitive
advantage;
| | - |  | ----------------------------------------------------------------------------------------------------------------------------------------------------------



| |  |  | greater experience in conducting research and development, manufacturing, clinical trials, obtaining regulatory clearance for products and marketing
approved products; and
| | - |  | ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------



| |  |  | greater financial and human resources for product development, sales and marketing, and patent litigation.
| | - |  | ----------------------------------------------------------------------------------------------------------

In addition, as the markets for medical devices develop, additional competitors could enter the market. As a result, we cannot assure you
that we will be able to compete successfully against existing or new competitors. Our revenues would be reduced or eliminated if our competitors develop and market products that are more effective and less expensive than our products.

We expect to continue to experience extended and variable sales cycles, which could cause significant variability in our results of
operations for any given quarter.

Our Sensei system has a lengthy sales cycle because it involves a relatively
expensive capital equipment purchase, which generally requires the approval of senior management at hospitals, inclusion in the hospitals electrophysiology laboratory budget process for capital expenditures and, in some instances, a
certificate of need from the state or other regulatory clearance. We continue to estimate that this sales cycle may take between six and 18 months. During the fourth quarter of 2008, in a period of economic



33



---

##### Table of Contents

uncertainty, we saw sales cycles for many potential customers lengthen and purchase decisions postponed. These factors have contributed in the past and may contribute in the future to substantial
fluctuations in our quarterly operating results, particularly in the near term and during any other periods in which our sales volume is relatively low. As a result, in future quarters our operating results could differ from our announcements of
guidance regarding future operating or financial results or may fail to meet the expectations of securities analysts or investors, in which event our stock price would likely decrease. These fluctuations also mean that you will not be able to rely
upon our operating results in any particular period as an indication of future performance. In addition, the introduction of new products could adversely impact our sales cycle, as customers take additional time to assess the benefits and
investments on capital products.

The use of our products could result in product liability claims that could be
expensive, divert managements attention and harm our reputation and business.

Our business exposes us to
significant risks of product liability claims that are inherent in the testing, manufacturing and marketing of medical devices. Moreover, the FDA has expressed concerns regarding the safety and efficacy of our Sensei system for ablation and other
therapeutic indications, including for the treatment of atrial fibrillation and has specifically instructed that our products be labeled to inform our customers that the safety and effectiveness of our technology for use with cardiac ablation
catheters in the treatment of cardiac arrhythmias, including for atrial fibrillation, have not been established. We presently believe that to date, all of the procedures in which our products have been used in the United States have included
off-label uses such as cardiac ablation, for which our Sensei system and Artisan catheters have not been cleared by the FDA and which therefore could increase the risk of product liability claims. The medical device industry has historically been
subject to extensive litigation over product liability claims. We may be subject to claims by consumers, healthcare providers, third-party payors or others selling our products if the use of our products were to cause, or merely appear to cause,
injury or death. Any weakness in training and services associated with our products may also result in product liability lawsuits. Although we maintain clinical trial liability and product liability insurance, the coverage is subject to deductibles
and limitations, and may not be adequate to cover future claims. Additionally, we may be unable to maintain our existing product liability insurance in the future at satisfactory rates or adequate amounts. A product liability claim, regardless of
its merit or eventual outcome could result in:



| |  |  | decreased demand for our products;
| | - |  | ----------------------------------



| |  |  | injury to our reputation;
| | - |  | -------------------------



| |  |  | diversion of managements attention;
| | - |  | ------------------------------------



| |  |  | withdrawal of clinical trial participants;
| | - |  | ------------------------------------------



| |  |  | significant costs of related litigation;
| | - |  | ----------------------------------------



| |  |  | payment of substantial monetary awards to patients;
| | - |  | ---------------------------------------------------



| |  |  | product recalls or market withdrawals;
| | - |  | --------------------------------------



| |  |  | loss of revenue; and
| | - |  | --------------------



| |  |  | the inability to commercialize our products under development.
| | - |  | --------------------------------------------------------------

We may be unable to complete the development and commercialization of our existing and anticipated products without additional
funding.

Our operations have consumed substantial amounts of cash since inception. We expect to continue to spend
substantial amounts on research and development. We expect to spend significant additional amounts on the continuing commercialization of our products and the development and introduction of new products. In the three months ended March 31,
2009, net cash used in operating activities was $6.0 million. We expect that our cash used by operations will be significant in each of the next several years, and we will need additional funds to continue the commercialization of our Sensei system.
Additional financing may not be available on a timely basis on terms acceptable to us, or at all. Furthermore, even if financing



34



---

##### Table of Contents

becomes available, the cost to us may be significantly higher than in the past. Any additional financing may be dilutive to stockholders or may require us to grant a lender a security interest in
our intellectual property assets. The amount of funding we will need will depend on many factors, including:



| |  |  | the success of our research and product development efforts;
| | - |  | ------------------------------------------------------------



| |  |  | the expenses we incur in selling and marketing our products;
| | - |  | ------------------------------------------------------------



| |  |  | the costs and timing of future regulatory clearances;
| | - |  | -----------------------------------------------------



| |  |  | the revenue generated by sales of our current and future products;
| | - |  | ------------------------------------------------------------------



| |  |  | the costs to scale-up manufacturing capacity;
| | - |  | ---------------------------------------------



| |  |  | the rate of progress and cost of our clinical trials and other development activities;
| | - |  | --------------------------------------------------------------------------------------



| |  |  | the emergence of competing or complementary technological developments;
| | - |  | -----------------------------------------------------------------------



| |  |  | the costs of filing, prosecuting, defending and enforcing any patent claims and other intellectual property rights, or participating in
litigation-related activities;
| | - |  | ----------------------------------------------------------------------------------------------------------------------------------------------------------------------



| |  |  | the terms and timing of any collaborative, licensing or other arrangements that we may establish; and
| | - |  | -----------------------------------------------------------------------------------------------------



| |  |  | the acquisition of businesses, products and technologies.
| | - |  | ---------------------------------------------------------

If adequate funds are not available, we may have to delay development or commercialization of our products or license to third parties the
rights to commercialize products or technologies that we would otherwise seek to commercialize. We also may have to reduce marketing, customer support or other resources devoted to our products. Any of these factors could harm our financial
condition.

Our products and related technologies can be applied in different applications, and we may fail to focus on
the most profitable areas.

Our Sensei system is designed to have the potential for applications beyond
electrophysiology, including in a variety of endoscopic procedures which require a control catheter to approach diseased tissue. We further believe that our Sensei system can provide multiple opportunities to improve the speed and capability of many
diagnostic and therapeutic procedures. We will be required to seek a separate 510(k) clearance or PMA approval from the FDA for these applications of our Sensei system. However, we have limited financial and managerial resources and therefore may be
required to focus on products in selected applications and to forego efforts with regard to other products and industries. Our decisions may not produce viable commercial products and may divert our resources from more profitable market
opportunities. Moreover, we may devote resources to developing products in these additional areas but may be unable to justify the value proposition or otherwise develop a commercial market for products we develop in these areas, if any. In that
case, the return on investment in these additional areas may be limited, which could negatively affect our results of operations.

If we fail to obtain or acquire imaging and visualization technology, or successfully collaborate with a strategic partner to provide such technology on terms favorable to us, or at all, our Sensei system may not be able to gain
market acceptance and our business may be harmed.

Our success depends on our ability to continually enhance and
broaden our product offerings in response to changing technologies, customer demands and competitive pressures. We believe that integrating our Sensei system with key imaging and visualization technologies using an open architecture approach is a
key element in establishing our Sensei system as important for complex interventional procedures. Our Sensei system currently utilizes a variety of imaging means to visualize and assist in navigating our Artisan catheters. These imaging systems
include fluoroscopy, intravascular ultrasound and electro-anatomic mapping systems, as well as pre-operatively acquired three-dimensional computed tomography and magnetic resonance imaging. We believe that in the future, as imaging companies develop
increasingly sophisticated three-dimensional imaging systems, we will need to integrate advanced imaging



35



---

##### Table of Contents

into our Sensei system in order to compete effectively. There can be no assurance that we can timely and effectively integrate these systems or components into our Sensei system in order to
remain competitive. We expect to face competition from companies that are developing new approaches and products for use in interventional procedures and that have an established presence in the field of interventional cardiology, including the
major imaging, capital equipment and disposables companies that are currently selling products in the electrophysiology laboratory. We may not be able to acquire or develop three-dimensional imaging and visualization technology for use with our
Sensei system. In addition, developing or acquiring key imaging and visualization technologies could be expensive and time-consuming and may not integrate well with our Sensei system. If we are unable to timely acquire, develop or integrate imaging
and visualization technologies, or any other changing technologies, effectively, our revenue may decline and our business will suffer.

In April 2007, we entered into agreements with St. Jude Medical, Inc., or St. Jude, to integrate our Sensei system with St. Judes Ensite system and to co-market the integrated product. We are not obligated to undertake any other
development projects except for the integration of the Sensei system with the EnSite system. We are solely responsible for gaining regulatory approvals for, and all costs associated with, our portion of the integrated products developed under the
arrangement. At the end of the second quarter of 2008, the FDA cleared for marketing in the United States our CoHesion Module, which provides an interface between our Sensei system and the EnSite system; however, there can be no assurance that we
will successfully maintain necessary regulatory clearances or that we and St. Jude will maintain compatibility of our products under the collaboration or that the CoHesion Module will gain market acceptance. We expect that in the second quarter of
2009 St. Jude will introduce a new version of its Ensite system that initially will not be compatible with our CoHesion Module, however St. Jude has indicated that it plans to achieve this compatibility over time. The initial lack of compatibility
may adversely affect the sales of the CoHesion Module and the Sensei system during the period.

In addition, under the terms
of the co-marketing agreement, we granted St. Jude the exclusive right to distribute products developed under the joint development agreement when ordered with St. Jude products worldwide, excluding certain specified countries, for the diagnosis
and/or treatment of certain cardiac conditions. There can be no assurance that we will successfully collaborate or that St. Jude will generate significant sales under this arrangement. If we are not able to successfully collaborate with St. Jude or
are unable to successfully integrate our systems, we may not be able to effectively compete with new technologies and our business may be harmed.

Our acquisition of AorTx, Inc. and future acquisitions are subject to a number of risks.

Our acquisition of AorTx, Inc., or AorTx, in November 2007 and the proposed completion of any future acquisitions will be subject to a number of risks, including:



| |  |  | with respect to future acquisitions, the possibility that an announced acquisition does not close;
| | - |  | --------------------------------------------------------------------------------------------------



| |  |  | the diversion of managements time and resources;
| | - |  | -------------------------------------------------



| |  |  | the difficulty of assimilating the operations and personnel of the acquired companies;
| | - |  | --------------------------------------------------------------------------------------



| |  |  | the potential disruption of our ongoing business;
| | - |  | -------------------------------------------------



| |  |  | the difficulty and cost of completing the development of and regulatory approval for technologies acquired at a development stage;
| | - |  | ----------------------------------------------------------------------------------------------------------------------------------



| |  |  | the difficulty of incorporating acquired technology and rights into our products and services;
| | - |  | ----------------------------------------------------------------------------------------------



| |  |  | unanticipated expenses related to integration of the acquired companies;
| | - |  | ------------------------------------------------------------------------



| |  |  | difficulties in implementing and maintaining uniform standards, controls, procedures and policies; and
| | - |  | ------------------------------------------------------------------------------------------------------



| |  |  | potential unknown liabilities associated with acquired businesses, including additional risks of third parties asserting claims that acquired
intellectual property infringes on the rights of such third parties.
| | - |  | ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------



36



---

##### Table of Contents

We acquired AorTx with the expectation that the acquisition would result in various benefits
including, among other things, leveraging our Sensei system into the developing market for percutaneous aortic heart valve replacement; however, we have decided to pursue this market opportunity independently from the development of AorTxs
technology. We have eliminated the research and development positions focused on developing the AorTx valve technology and while we continue to pursue the application of robotics to structural heart procedures, we do not expect that the technologies
acquired from AorTx will form a material, or any, part of that strategy. Pursuant to the terms of the AorTx acquisition, we have decided to license the acquired AorTx technologies back to an entity to be formed by the former AorTx stockholders
rather than be required to make a $5 million payment to the former AorTx stockholders on May 15, 2009. As a result of this decision to license the technologies back, rather than make the payment, or if other risks associated with acquisitions
materialize, our stock price could be adversely affected.

Software defects may be discovered in our products.

Our Sensei system incorporates sophisticated computer software. Complex software frequently contains errors, especially when
first introduced. Because our products are designed to be used to perform complex interventional procedures, we expect that physicians and hospitals will have an increased sensitivity to the potential for software and other defects. We cannot assure
you that our software will not experience errors or performance problems in the future. If we experience software errors or performance problems, we would likely also experience:



| |  |  | loss of revenue;
| | - |  | ----------------



| |  |  | an increase in reportable adverse events to applicable authorities such as the FDA;
| | - |  | -----------------------------------------------------------------------------------



| |  |  | delay in market acceptance of our products;
| | - |  | -------------------------------------------



| |  |  | damage to our reputation;
| | - |  | -------------------------



| |  |  | additional regulatory filings;
| | - |  | ------------------------------



| |  |  | product recalls;
| | - |  | ----------------



| |  |  | increased service or warranty costs; and/or
| | - |  | -------------------------------------------



| |  |  | product liability claims relating to the software defects.
| | - |  | ----------------------------------------------------------

Our costs could substantially increase if we receive a significant number of warranty claims.

We warrant each of our products against defects in materials and workmanship for a period of approximately 12 months from the delivery or
acceptance of our product by a customer which is normally when the system is installed. We accrue the estimated cost of warranties at the time revenue is recognized; however, we have a very limited history of commercial placements from which to
judge our rate of warranty claims. Our warranty obligation may be impacted by product failure rates, material usage and warranty service costs. We periodically evaluate and adjust the warranty reserve to the extent actual warranty expense differs
from the original estimates, and, if warranty claims are significant or differ significantly from estimates, we could incur additional expenditures for parts and service and our reputation and goodwill in the electrophysiology lab market could be
damaged. Unforeseen warranty exposure in excess of our reserves could negatively impact our business, financial condition and results of operations.

Hospitals or physicians may be unable to obtain coverage or reimbursement from third-party payors for procedures using our Sensei system, which could affect the adoption or use of our Sensei system
and may cause our revenues to decline.

We anticipate that third-party payors will continue to reimburse hospitals and
physicians under existing billing codes for the vast majority of the procedures involving our products. We expect that healthcare facilities and physicians in the United States will continue to bill various third-party payors, such as Medicare,
Medicaid, other governmental programs and private insurers, for services performed using our products. We believe that procedures targeted for use with our products are generally already reimbursable



37



---

##### Table of Contents

under government programs and most private plans. Accordingly, we believe providers in the United States will generally not be required to obtain new billing authorizations or codes in order to
be compensated for performing medically necessary procedures using our products on insured patients.

There can be no
assurance, however, that coverage, coding and reimbursement policies of third-party payors will not change in the future with respect to some or all of the procedures that would use our Sensei system. Additionally, in the event that a physician uses
our Sensei system for indications not approved by the FDA, there can be no assurance that the coverage or reimbursement policies of third-party payors will be comparable to FDA-approved uses. Future legislation, regulation or coverage, coding and
reimbursement policies of third-party payors may adversely affect the demand for our products currently under development and limit our ability to profitably sell our products. For example, under recent regulatory changes to the methodology for
calculating payments for current inpatient procedures in certain hospitals, Medicare payment rates for surgical and cardiac procedures have been decreased, including those procedures for which our products are targeted. The majority of the
procedures performed with our Sensei system and Artisan catheter are done on an in-patient basis and thus are paid under the Medicare-severity diagnosis related group, or MS-DRG system. We believe that the majority of procedures performed using our
technology fall under MS-DRG 251, percutaneous cardiovascular procedures without coronary artery stent or acute myocardial infarction without major cardiovascular complication, with an average reimbursement of $9,260 for fiscal 2008. The
Center for Medicare and Medicaid services updates the MSDRG annually effective October 1 through September 30th of the following year. The proposed rule stating anticipated changes will be published June 2009 with a period for comments and
the final rule becoming effective October 1, 2010. Because hospital inpatient reimbursement is largely dependent on geographical location and other hospital-specific factors, an individual hospitals revenues from ablation procedures to
treat atrial fibrillation using our technology can vary significantly. At this time, we cannot predict the full impact any rate reductions will have on our future revenues or business.

Our success in international markets also depends upon the eligibility of our products for coverage and reimbursement by
government-sponsored healthcare payment systems and third-party payors. In both the United States and foreign markets, healthcare cost-containment efforts are prevalent and are expected to continue. The failure of our customers to obtain sufficient
reimbursement could have a material adverse impact on our financial condition and harm our business.

We may lose our
key personnel or fail to attract and retain additional personnel.

We are highly dependent on the principal members of
our management and scientific staff, in particular Frederic Moll, M.D., our Founder and Chief Executive Officer and one of our directors. Dr. Moll has extensive experience in the medical device industry, and we believe his expertise in the
robotic device field may enable us to have proposals reviewed by key hospital decision-makers earlier in the sales process than may otherwise be the case. We do not carry key person insurance covering any members of our senior
management. Each of our officers and key employees may terminate his employment at any time without notice and without cause or good reason. The loss of any of these persons could prevent the implementation and completion of our objectives,
including the development and introduction of our products, and could require the remaining management members to direct immediate and substantial attention to seeking a replacement.

Additionally, in the third quarter of 2008 and the first quarter of 2009, we reduced our work force. This may make it more difficult to
retain and attract the qualified personnel required, placing a significant strain on our management. Accordingly, retaining such personnel and recruiting necessary new employees in the future will be critical to our success. There is intense
competition from other companies and research and academic institutions for qualified personnel in the areas of our activities. If we fail to identify, attract, retain and motivate these highly skilled personnel, we may be unable to continue our
development and commercialization activities.



38



---

##### Table of Contents

If we do not effectively manage our growth, we may be unable to successfully develop,
market and sell our products.

Our future revenue and operating results will depend on our ability to manage the
anticipated growth of our business. We have experienced significant growth in the scope of our operations since our inception. This growth has placed significant demands on our management, as well as our financial and operations resources. In order
to achieve our business objectives, however, we will need to continue to grow, which presents numerous challenges, including:



| |  |  | implementing appropriate operational and financial systems and controls;
| | - |  | ------------------------------------------------------------------------



| |  |  | expanding manufacturing capacity, increasing production and improving margins;
| | - |  | ------------------------------------------------------------------------------



| |  |  | developing our sales and marketing infrastructure and capabilities;
| | - |  | -------------------------------------------------------------------



| |  |  | identifying, attracting and retaining qualified personnel in our areas of activity; and
| | - |  | ---------------------------------------------------------------------------------------



| |  |  | training, managing and supervising our personnel worldwide.
| | - |  | -----------------------------------------------------------

Any failure to effectively manage our growth could impede our ability to successfully develop, market and sell our products and our business
will be harmed.

We commenced sales of our Sensei system internationally and are subject to various risks relating to
such international activities which could adversely affect our international sales and operating performance.

A
portion of our current and future revenues will come from international sales. To expand internationally, we will need to hire, train and retain additional qualified personnel. Engaging in international business inherently involves a number of
difficulties and risks, including:



| |  |  | required compliance with existing and changing foreign regulatory requirements and laws;
| | - |  | ----------------------------------------------------------------------------------------



| |  |  | export or import restrictions and controls relating to technology;
| | - |  | ------------------------------------------------------------------



| |  |  | pricing pressure;
| | - |  | -----------------



| |  |  | laws and business practices favoring local companies;
| | - |  | -----------------------------------------------------



| |  |  | longer payment cycles;
| | - |  | ----------------------



| |  |  | the effects of fluctuations in foreign currency exchange rates;
| | - |  | ---------------------------------------------------------------



| |  |  | shipping delays;
| | - |  | ----------------



| |  |  | difficulties in enforcing agreements and collecting receivables through certain foreign legal systems;
| | - |  | ------------------------------------------------------------------------------------------------------



| |  |  | political and economic instability;
| | - |  | -----------------------------------



| |  |  | potentially adverse tax consequences, tariffs and other trade barriers;
| | - |  | -----------------------------------------------------------------------



| |  |  | international terrorism and anti-American sentiment;
| | - |  | ----------------------------------------------------



| |  |  | difficulties in penetrating markets in which our competitors products are more established;
| | - |  | --------------------------------------------------------------------------------------------



| |  |  | difficulties and costs of staffing and managing foreign operations; and
| | - |  | -----------------------------------------------------------------------



| |  |  | difficulties in enforcing intellectual property rights.
| | - |  | -------------------------------------------------------

If one or more of these risks are realized, it could require us to dedicate significant resources to remedy the situation, and if we are
unsuccessful at finding a solution, our revenue may decline.



39



---

##### Table of Contents

Our business may be harmed by a natural disaster, terrorist attacks or other
unanticipated problems.

Our manufacturing and office facilities are located in Mountain View, California. Despite
precautions taken by us, a natural disaster such as fire or earthquake, a terrorist attack or other unanticipated problems at our facilities could interrupt our ability to manufacture our products or operate our business. These disasters or problems
may also destroy our product inventories. While we carry insurance for certain natural disasters and business interruption, any prolonged or repeated disruption or inability to manufacture our products or operate our business could result in losses
that exceed the amount of coverage provided by this insurance, and in such event could harm our business.

We may be
liable for contamination or other harm caused by materials that we handle, and changes in environmental regulations could cause us to incur additional expense.

Our research and development, manufacturing and clinical processes involve the handling of potentially harmful biological materials as well as other hazardous materials. We are subject to federal, state
and local laws and regulations governing the use, handling, storage and disposal of hazardous and biological materials and we incur expenses relating to compliance with these laws and regulations. If violations of environmental, health and safety
laws occur, we could be held liable for damages, penalties and costs of remedial actions. These expenses or this liability could have a significant negative impact on our financial condition. We may violate environmental, health and safety laws in
the future as a result of human error, equipment failure or other causes. Environmental laws could become more stringent over time, imposing greater compliance costs and increasing risks and penalties associated with violations. We are subject to
potentially conflicting and changing regulatory agendas of political, business and environmental groups. Changes to or restrictions on permitting requirements or processes, hazardous or biological material storage or handling might require an
unplanned capital investment or relocation. Failure to comply with new or existing laws or regulations could harm our business, financial condition and results of operations.

Changes to existing accounting pronouncements or taxation rules or practices may affect how we conduct our business and affect our
reported results of operations.

A change in accounting pronouncements or taxation rules or practices can have a
significant effect on our reported results and may even affect our reporting of transactions completed before the change is effective. During the first quarter of fiscal 2006, we adopted the provisions of the Financial Accounting Standards
Boards Statement of Financial Accounting Standards No. 123 (revised 2004), or SFAS No. 123(R), Share-Based Payment, which replaced Statement of Financial Accounting Standards No. 123, or SFAS 123, Accounting for
Stock-Based Compensation and superseded APB Opinion No. 25, Accounting for Stock Issued to Employees. Adoption of this statement has had a significant impact on our financial statements since 2006 and is expected to have a
significant impact on our future financial statements, as we are now required to expense the fair value of our stock option grants and stock purchases under our employee stock purchase plan rather than disclose the impact on our net loss within our
footnotes. Other new accounting pronouncements or taxation rules and varying interpretations of accounting pronouncements or taxation practice have occurred and may occur in the future. Changes to existing rules, future changes, if any, or the
questioning of current practices may adversely affect our reported financial results or the way we conduct our business.

We have a debt facility with Silicon Valley Bank that requires us to meet certain restrictive covenants that may limit our operating flexibility.

In August 2008, we entered into a $25 million loan and security agreement with Silicon Valley Bank, consisting of a $15 million term equipment loan and a one-year $10 million revolving credit line. We
have drawn down approximately $12.5 million on the term equipment loan and, as of March 31, 2009, the remainder of the term equipment loan is no longer available per the original agreement terms. The facility is collateralized by substantially
all of our assets, excluding intellectual property, and is subject to certain covenants, including maintaining the required liquidity, achieving the specified EBITDA amounts and



40



---

##### Table of Contents

fulfilling certain reporting requirements. The liquidity covenants require us to maintain at the end of each month either liquid assets in the amount of 1.5 times the outstanding loan balance or
sufficient liquidity to fund at least six months of projected operations, whichever is greater. We will become subject to EBITDA requirements beginning with the second quarter of 2009. Silicon Valley Bank has yet to determine the quarterly EBITDA
amounts with us. As of March 31, 2009, we were in compliance with all financial covenants. If we fail to comply with any of the loan covenants, we could be deemed to have an event of default. In the case of an event of default, we could be
required to immediately remit all outstanding funds then due under the facility; or prepare our collateral for sale to satisfy the amount of outstanding funds owed to Silicon Valley Bank. Moreover, the agreement limits our ability to take the
following corporate actions without prior consent from Silicon Valley Bank:



| |  |  | transfer all or any part of our business or properties, other than transfers made in the ordinary course of business;
| | - |  | ---------------------------------------------------------------------------------------------------------------------



| |  |  | engage in any business other than the business in which we are currently engaged;
| | - |  | ---------------------------------------------------------------------------------



| |  |  | merge or consolidate with any other person, or acquire, all or substantially all of the capital stock or property of another person, subject to certain
exceptions;
| | - |  | -------------------------------------------------------------------------------------------------------------------------------------------------------------------



| |  |  | create, incur, assume, or be liable for any indebtedness, other than certain permitted indebtedness;
| | - |  | ----------------------------------------------------------------------------------------------------



| |  |  | pay any dividends or make any distribution or payment or redeem, retire or purchase any capital stock, subject to certain exceptions;
| | - |  | -------------------------------------------------------------------------------------------------------------------------------------



| |  |  | create, incur, allow or suffer any lien on any of our property, including without limitation intellectual property, assign or convey any right to
receive income;
| | - |  | -----------------------------------------------------------------------------------------------------------------------------------------------------------------



| |  |  | directly or indirectly enter into or permit to exist any material transaction with any of our affiliates, subject to certain exceptions; and
| | - |  | --------------------------------------------------------------------------------------------------------------------------------------------



| |  |  | make or permit any payment on any subordinated debt.
| | - |  | ----------------------------------------------------

Complying with these covenants may make it more difficult for us to successfully execute our business strategy.

Risks Related to Our Intellectual Property

If we are unable to
protect the intellectual property contained in our products from use by third parties, our ability to compete in the market will be harmed.

Our commercial success will depend in part on obtaining patent and other intellectual property protection for the technologies contained in our products, and on successfully defending our patents and
other intellectual property against third party challenges. We expect to incur substantial costs in obtaining patents and, if necessary, defending our proprietary rights. The patent positions of medical device companies, including ours, can be
highly uncertain and involve complex and evolving legal and factual questions. We do not know whether we will be able to obtain the patent protection we seek, or whether the protection we do obtain will be found valid and enforceable if challenged.
We also do not know whether we will be able to develop additional patentable proprietary technologies. If we fail to obtain adequate protection of our intellectual property, or if any protection we obtain is reduced or eliminated, others could use
our intellectual property without compensating us, resulting in harm to our business. We may also determine that it is in our best interests to voluntarily challenge a third partys products or patents in litigation or administrative
proceedings, including patent interferences or reexaminations. In the event that we seek to enforce any of our owned or exclusively licensed patents against an infringing party, it is likely that the party defending the claim will seek to invalidate
the patents we assert, which, if successful could result in the loss of the entire patent or the relevant portion of our patent, which would not be limited to any particular party. Any litigation to enforce or defend our patent rights, even if we
were to prevail, could be costly and time-consuming and could divert the attention of our management and key personnel from our business operations. Our competitors may independently develop similar or alternative technologies or products without
infringing any of our patent or other intellectual property rights, or may design around our proprietary technologies.



41



---

##### Table of Contents

We cannot assure you that we will obtain the patent protection we seek, that any protection
we do obtain will be found valid and enforceable if challenged or that such patent protection will confer any significant commercial advantage. United States patents and patent applications may also be subject to interference proceedings and United
States patents may be subject to reexamination proceedings in the United States Patent and Trademark Office, and foreign patents may be subject to opposition or comparable proceedings in the corresponding foreign patent offices, which proceedings
could result in either loss of the patent or denial of the patent application, or loss or reduction in the scope of one or more of the claims of, the patent or patent application. In addition, such interference, reexamination and opposition
proceedings may be costly. Some of our technology was, and continues to be, developed in conjunction with third parties, and thus there is a risk that such third parties may claim rights in our intellectual property. Thus, any patents that we own or
license from others may provide limited or no protection against competitors. Our pending patent applications, those we may file in the future, or those we may license from third parties, may not result in patents being issued. If issued, they may
not provide us with proprietary protection or competitive advantages against competitors with similar technology.

Non-payment
or delay in payment of patent fees or annuities, whether intentional or unintentional, may result in loss of patents or patent rights important to our business. Many countries, including certain countries in Europe, have compulsory licensing laws
under which a patent owner may be compelled to grant licenses to third parties. In addition, many countries limit the enforceability of patents against third parties, including government agencies or government contractors. In these countries, the
patent owner may have limited remedies, which could materially diminish the value of the patent. In addition, the laws of some foreign countries do not protect intellectual property rights to the same extent as do the laws of the United States,
particularly in the field of medical products and procedures.

Our trade secrets, nondisclosure agreements and other
contractual provisions to protect unpatented technology provide only limited and possibly inadequate protection of our rights. As a result, third parties may be able to use our unpatented technology, and our ability to compete in the market would be
reduced. In addition, employees, consultants and others who participate in developing our products or in commercial relationships with us may breach their agreements with us regarding our intellectual property, and we may not have adequate remedies
for the breach.

Third parties may assert that we are infringing their intellectual property rights which may result in
litigation.

Successfully commercializing our Sensei system, and any other products we may develop, will depend in
part on our not infringing patents held by third parties. It is possible that one or more of our products, including those that we have developed in conjunction with third parties, infringes existing patents. From time to time, we have received, and
likely will continue to receive, communications from third parties inviting us to license their patents or accusing us of infringement. There can be no assurance that a third party will not take further action, such as filing a patent infringement
lawsuit, including a request for injunctive relief, to bar the manufacture and sale of our Sensei system in the United States or elsewhere. We may also choose to defend ourselves by initiating litigation or administrative proceedings to clarify or
seek a declaration of our rights. As competition in our market grows, the possibility of a patent infringement claim against us or litigation we will initiate increases.

There may be existing patents which may be broad enough to cover aspects of our future technology. In addition, because patent applications in many countries such as the United States are maintained under
conditions of confidentiality and can take many years to issue, there may be applications now pending of which we are unaware and which may later result in issued patents that our products infringe. We do not know whether any of these patents, if
challenged, would be upheld as valid, enforceable and infringed by our products or technology. From time to time, we receive, and likely will continue to receive, letters from third parties accusing us of infringing their patents or inviting us to
license their patents. We may be sued by, or become involved in an administrative proceeding with, one or more of these or other third parties. We cannot assure you that a court or administrative body would agree with any arguments or defenses we
may present concerning the invalidity, unenforceability or noninfringement of any third-party patent.



42



---

##### Table of Contents

In addition to the issued patents of which we are aware, other parties may have filed, and in the future are likely to file, patent applications covering products that are similar or identical to
ours. We cannot assure you that any patents issuing from applications will not cover our products or will not have priority over our own products and patent applications.

We may not be able to maintain or obtain all the licenses from third parties necessary or advisable for promoting, manufacturing and selling our Sensei system, which may cause harm to our business,
operations and financial condition.

We rely on technology that we license from others, including technology that is
integral to our Sensei system, such as patents and other intellectual property that we have co-exclusively licensed from Intuitive. Under our agreement with Intuitive, we received the right to apply Intuitives patent portfolio in the field of
intravascular approaches for the diagnosis or treatment of cardiovascular, neurovascular and peripheral vascular diseases. To the extent that we develop or commercialize robotic capability outside the field of use covered by our license with
Intuitive, which we may choose to do at some time in the future, we may not have the patent protection and the freedom to operate outside the field which is afforded by the license inside the field. Although we believe that there are opportunities
for us to operate outside the licensed field of use without using Intuitives intellectual property, Intuitive from time to time has told us that it believes certain of our past activities that have fallen outside the licensed field have
infringed its intellectual property rights. Although we disagree with Intuitives position, we presently remain focused within our licensed field and so have agreed to inform Intuitive before commencing any further outside clinical
investigations for endoluminal applications or engaging in external technology exhibitions at non-intravascular conferences. There can be no assurance that Intuitive will not challenge any activities we engage in outside the intravascular space, and
we cannot assure you that in the event of such a challenge we would be able to reach agreement with Intuitive on whether activities outside our licensed field may be conducted without the use of the Intuitives intellectual property. If
Intuitive asserts that any of our activities outside the licensed field are infringing their patent or other intellectual property rights or commences litigation against us, we will incur significant costs defending against such claims or seeking an
additional license from Intuitive, and we may be required to limit use of our Sensei system or future products and technologies within our licensed intravascular field if any of our activities outside the licensed field are judged to infringe
Intuitives intellectual property, any of which could cause substantial harm our business, operations and financial condition. Although Intuitive is restricted in how it can terminate our license, if Intuitive were ever to successfully do so,
and if we are unable to obtain another license from Intuitive, we could be required to abandon use of our existing Sensei technology completely and could have to undergo a substantial redesign and design-around effort, which we cannot assure you
would be successful.

The medical device industry is characterized by patent litigation and we could become subject to
litigation that could be costly, result in the diversion of managements attention, require us to pay damages and discontinue selling our products.

The medical device industry is characterized by frequent and extensive litigation and administrative proceedings over patent and other intellectual property rights. Whether a product infringes a patent
involves complex legal and factual issues, the determination of which is often difficult to predict, and the outcome may be uncertain until the court has entered final judgment and all appeals are exhausted. Our competitors may assert, and have
asserted in the past, that our products or the use of our products are covered by United States or foreign patents held by them. This risk is heightened due to the numerous issued and pending patents relating to the use of robotic and catheter-based
procedures in the medical technology field. For example, we have received correspondence from a third party indicating it believes it holds a patent that our Sensei system may infringe. While we do not believe that the Sensei system infringes this
patent, there can be no assurance that the third party will not take further action, such as filing a patent infringement lawsuit, including a request for injunctive relief, to bar the manufacture and sale of our Sensei system in the United States.

If relevant patents are upheld as valid and enforceable and we are found to infringe, we could be prevented from selling our
system unless we can obtain a license to use technology or ideas covered by



43



---

##### Table of Contents

such patent or are able to redesign our Sensei system to avoid infringement. A license may not be available at all or on commercially reasonable terms, and we may not be able to redesign our
products to avoid infringement. Modification of our products or development of new products could require us to conduct additional clinical trials and to revise our filings with the FDA and other regulatory bodies, which would be time-consuming and
expensive. If we are not successful in obtaining a license or redesigning our products, we may be unable to sell our products and our business could suffer. In addition, our patents may be subject to various invalidity attacks, such as those based
upon earlier filed patent applications, patents, publications, products or processes, which might invalidate or limit the scope of the protection that our patents afford.

Infringement actions, validity challenges and other intellectual property claims and proceedings, whether with or without merit, may cause us to incur substantial costs and could place a significant
strain on our financial resources, divert the attention of management from our business and harm our reputation. We have incurred, and expect to continue to incur, substantial costs in obtaining patents and expect to incur substantial costs
defending our proprietary rights. Incurring such costs could have a material adverse effect on our financial condition, results of operations and cash flow.

We cannot be certain that we will successfully defend our patents from infringement or claims of invalidity or unenforceability, or that we will successfully defend against allegations of infringement of
third-party patents. In addition, any public announcements related to litigation or administrative proceedings initiated or threatened by us, or initiated or threatened against us, could cause our stock price to decline.

We may be subject to damages resulting from claims that our employees or we have wrongfully used or disclosed alleged trade secrets of
their former employers.

Many of our employees were previously employed at universities or other medical device
companies, including our competitors or potential competitors. We could in the future be subject to claims that these employees, or we, have inadvertently or otherwise used or disclosed trade secrets or other proprietary information of their former
employers. Litigation may be necessary to defend against these claims. If we fail in defending against such claims, a court could order us to pay substantial damages and prohibit us from using technologies or features that are essential to our
products, if such technologies or features are found to incorporate or be derived from the trade secrets or other proprietary information of the former employers. An inability to incorporate technologies or features that are important or essential
to our products would have a material adverse effect on our business, and may prevent us from selling our products. In addition, we may lose valuable intellectual property rights or personnel. A loss of key research personnel or their work product
could hamper or prevent our ability to commercialize certain potential products, which could severely harm our business. Even if we are successful in defending against these claims, such litigation could result in substantial costs and be a
distraction to management. Incurring such costs could have a material adverse effect on our financial condition, results of operations and cash flow.

Additional Risks Related to Regulatory Matters

If we fail to obtain regulatory clearances in other
countries for products under development, we will not be able to commercialize these products in those countries.

In
order to market our products outside of the United States, we must establish and comply with numerous and varying regulatory requirements of other countries regarding safety and efficacy. Approval procedures vary among countries and can involve
additional product testing and additional administrative review periods. The time required to obtain approval in other countries might differ from that required to obtain FDA clearance. The regulatory approval process in other countries may include
all of the risks detailed above regarding FDA clearance in the United States. Regulatory approval in one country does not ensure regulatory approval in another, but a failure or delay in obtaining regulatory approval in one country may negatively
impact the regulatory process in others. Failure to obtain regulatory approval in other countries or any delay or setback in obtaining such approval could have the same adverse effects described above regarding FDA clearance in the United States.



44



---

##### Table of Contents

For example, the European Union requires that medical products receive the right to affix
the CE mark. The CE mark is an international symbol of adherence to quality assurance standards and compliance with applicable European medical device directives. In order to obtain the right to affix the CE mark to our products, we will need to
obtain certification that our processes meet European quality standards. These standards include certification that our product design and manufacturing facility complies with ISO 13485 quality standards. We received CE mark approval for our Artisan
catheters in May 2007. However, future regulatory approvals may be needed. We cannot be certain that we will be successful in meeting European quality standards or other certification requirements.

We may fail to comply with continuing postmarket regulatory requirements of the FDA and other authorities and become subject to
substantial penalties, or marketing experience may show that our device is unsafe, forcing us to recall or withdraw it permanently from the market.

We must comply with continuing regulation by the FDA and other authorities, including the FDAs Quality System Regulation, or QSR, requirements, labeling and promotional requirements and medical
device adverse event and other reporting requirements. If the adverse event reports we file with the FDA regarding death, serious injuries or malfunctions indicate or suggest that the device presents an unacceptable risk to patients, including when
used off-label by physicians, we may be forced to recall the device and/or modify the device or its labeling, or withdraw it permanently from the market. The FDA has expressed concerns regarding the safety of the device when used with catheters and
in procedures not specified in the indication we are seeking, such as ablation catheters and ablation procedures, and we have already filed Medical Device Reports reporting adverse events during procedures utilizing our technology. Physicians are
using our device off-label with ablation catheters in ablation procedures, as well as in other electrophysiology procedures for which we have not collected safety data, and we therefore cannot assure you that clinical experience will demonstrate
that the device is safe for these uses.

Any failure to comply, or any perception that we are not complying, with continuing
regulation by the FDA or other authorities, including restrictions regarding off-label promotion, could result in enforcement action that may include suspension or withdrawal of regulatory clearances or approvals, recalling products, ceasing product
marketing, seizure and detention of products, paying significant fines and penalties, criminal prosecution and similar actions that could limit product sales, delay product shipment and harm our profitability.

In many foreign countries in which we market our products, we are subject to regulations affecting, among other things, product standards,
packaging requirements, labeling requirements, import restrictions, tariff regulations, duties and tax requirements. Many of these regulations are similar to those of the FDA. In addition, in many countries the national health or social security
organizations require our products to be qualified before procedures performed using our products become eligible for coverage and reimbursement. Failure to receive, or delays in the receipt of, relevant foreign qualifications could have a material
adverse effect on our business, financial condition and results of operations. Due to the movement toward harmonization of standards in the European Union, we expect a changing regulatory environment in Europe characterized by a shift from a
country-by-country regulatory system to a European Union-wide single regulatory system. The timing of this harmonization and its effect on us cannot currently be predicted. Adapting our business to changing regulatory systems could have a material
adverse effect on our business, financial condition and results of operations. If we fail to comply with applicable foreign regulatory requirements, we may be subject to fines, suspension or withdrawal of regulatory clearances, product recalls,
seizure of products, operating restrictions and criminal prosecution.

If we or our contract manufacturers fail to
comply with the FDA's Quality System Regulations or California Department of Health Services requirements, our manufacturing operations could be interrupted and our product sales and operating results could suffer.

Our manufacturing processes, and those of some of our contract manufacturers, are required to comply with the FDAs Quality System
Regulations, or QSR, which cover the procedures and documentation of the design, testing, production, control, quality assurance, labeling, packaging, sterilization, storage and shipping of our devices. The FDA enforces the QSR through periodic
inspections of manufacturing facilities. We and our contract manufacturers are subject to such inspections. If our



45



---

##### Table of Contents

manufacturing facilities or those of any of our contract manufacturers fail to take satisfactory corrective action in response to an adverse QSR inspection, the FDA could take enforcement action,
including any of the following sanctions, which could have a material impact on our operations:



| |  |  | untitled letters, warning letters, fines, injunctions, consent decrees and civil penalties;
| | - |  | -------------------------------------------------------------------------------------------



| |  |  | unanticipated expenditures to address or defend such actions;
| | - |  | -------------------------------------------------------------



| |  |  | customer notifications for repair, replacement, refunds;
| | - |  | --------------------------------------------------------



| |  |  | recall, detention or seizure of our products;
| | - |  | ---------------------------------------------



| |  |  | operating restrictions or partial suspension or total shutdown of production;
| | - |  | -----------------------------------------------------------------------------



| |  |  | refusing or delaying our requests for 510(k) clearance or premarket approval of new products or modified products;
| | - |  | ------------------------------------------------------------------------------------------------------------------



| |  |  | operating restrictions;
| | - |  | -----------------------



| |  |  | withdrawing 510(k) clearances on PMA approvals that have already been granted;
| | - |  | ------------------------------------------------------------------------------



| |  |  | refusal to grant export approval for our products; or
| | - |  | -----------------------------------------------------



| |  |  | criminal prosecution.
| | - |  | ---------------------

We are subject to the licensing requirements of the California Department of Health Services, or CDHS. We have been inspected and licensed by the CDHS and remain subject to re-inspection at any time.
Failure to maintain a license from the CDHS or to meet the inspection criteria of the CDHS would disrupt our manufacturing processes. If an inspection by the CDHS indicates that there are deficiencies in our manufacturing process, we could be
required to take remedial actions at potentially significant expense, and our facility may be temporarily or permanently closed.

If our products cause or contribute to a death or a serious injury, or malfunction in certain ways, we will be subject to medical device reporting regulations, which can result in voluntary corrective actions or agency enforcement
actions. An increased frequency of filing Medical Device Reports concerning adverse events occurring during procedures performed with our technology could result in increased regulatory scrutiny of our products and could delay or prevent the
adoption of our products.

Under the FDA medical device reporting regulations, medical device manufacturers are
required to report to the FDA information that a device has or may have caused or contributed to a death or serious injury or has malfunctioned in a way that would likely cause or contribute to death or serious injury if the malfunction of the
device or one of our similar devices were to recur. If we fail to report these events to the FDA within the required timeframes, or at all, FDA could take enforcement action against us. Any such adverse event involving our products also could result
in future voluntary corrective actions, such as recalls or customer notifications, or agency action, such as inspection or enforcement action. Any corrective action, whether voluntary or involuntary, as well as defending ourselves in a lawsuit, will
require the dedication of our time and capital, distract management from operating our business, and may harm our reputation and financial results.

We have filed Medical Device Reports, or MDRs, reporting adverse events during procedures utilizing our technology and have developed internal systems and processes that are designed to evaluate future
events that may require adverse event reporting to the FDA. As the frequency of use of our technology in electrophysiology procedures increases, we are experiencing, and anticipate continuing to experience, it being necessary to file an increased
number of MDRs. An increased frequency of filing MDRs or a failure to timely file MDRs may result in FDA requests for further information, which could delay other matters that we may have pending before the FDA, or result in additional regulatory
action. An increased frequency of MDRs could also reduce confidence in the safety of our products and delay or prevent the acceptance of our products by physicians and hospitals, which would harm our business and cause our stock price to decline.



46



---

##### Table of Contents

Our products may in the future be subject to product recalls that could harm our
reputation, business and financial results.

The FDA and similar foreign governmental authorities have the authority
to require the recall of commercialized products in the event of material deficiencies or defects in design or manufacture. In the case of the FDA, the authority to require a recall must be based on an FDA finding that there is a reasonable
probability that the device would cause serious injury or death. In addition, foreign governmental bodies have the authority to require the recall of our products in the event of material deficiencies or defects in design or manufacture.
Manufacturers may, under their own initiative, recall a product if any material deficiency in a device is found. A government-mandated or voluntary recall by us or one of our distributors could occur as a result of component failures, manufacturing
errors, design or labeling defects or other deficiencies and issues. For example, in May 2008, we initiated a voluntary recall of a limited number of our Artisan Control Catheters that were subject to potential leakage, and reported the recall to
FDA in accordance with applicable regulations. No patient is known or suspected to have experienced any consequences associated with the recalled devices and the recall was closed in June 2008. Recalls of any of our products would divert managerial
and financial resources and have an adverse effect on our financial condition and results of operations. The FDA requires that certain classifications of recalls be reported to FDA within 10 working days after the recall is initiated. Companies are
required to maintain certain records of recalls, even if they are not reportable to the FDA. We may initiate voluntary recalls involving our products in the future that we determine do not require notification of the FDA. If the FDA disagrees with
our determinations, they could require us to report those actions as recalls. A future recall announcement could harm our reputation with customers and negatively affect our sales. In addition, the FDA could take enforcement action for failing to
report the recalls when they were conducted.

Modifications to our products may, and in some instances, will, require
new regulatory clearances or approvals and may require us to recall or cease marketing our products until clearances or approvals are obtained.

Modifications to our products may require new regulatory approvals or clearances, including 510(k) clearances or premarket approvals, or PMAs, and may require us to recall or cease marketing the modified
devices until these clearances or approvals are obtained. The FDA requires device manufacturers to initially make and document in a letter to file a determination of whether or not a modification requires a new approval, supplement or
clearance. A manufacturer of a 510(k) cleared product may determine that a modification could not significantly affect safety or efficacy and does not represent a major change in its intended use so that no new 510(k) clearance is necessary.
However, the FDA can review a manufacturers decision and may disagree. The FDA may also on its own initiative determine that a new clearance or approval is required.

We have made modifications to our products in the past and may make additional modifications in the future that we believe do not or will
not require additional clearances or approvals because we believe they can be made on a letter-to-file approach. There can be no assurance that the FDA will agree with our approach in such matters or that, if required, subsequent requests for 510(k)
clearance will be received in a timely fashion, if at all. The FDA may require us to recall and to stop marketing our products as modified or to disable features pending clearance or approval which would significantly harm our ability to sell our
products and cause harm to our existing customer relationships and business. Even if we are not required to take such action, delays in obtaining clearances or approvals for features would adversely affect our ability to introduce enhanced products
in a timely manner and would harm our revenue and operating results. The FDA could also take other enforcement action, including but not limited to, issuing a warning letter relating to our decision to implement features and other product
modifications via a letter to file rather than submission of a new 510(k) notice.



47



---

##### Table of Contents

Clinical trials necessary to support any future 510(k) or PMA application will be
expensive and may require the enrollment of large numbers of patients, and suitable patients may be difficult to identify and recruit. Delays or failures in our clinical trials may prevent us from commercializing any modified or new products and
will adversely affect our business, operating results and prospects.

If required by the FDA to do so, initiating and
completing clinical trials necessary to support a 510(k) or PMA application for expanded indications for use of our existing products, will be time consuming and expensive and the outcome uncertain. Moreover, the results of early clinical trials are
not necessarily predictive of future results, and any product we advance into clinical trials may not have favorable results in later clinical trials.

Conducting successful clinical studies may require the enrollment of large numbers of patients, and suitable patients may be difficult to identify and recruit. Patient enrollment in clinical trials and
completion of patient participation and follow-up depends on many factors, including the size of the patient population, the nature of the trial protocol, the attractiveness of, or the discomforts and risks associated with, the treatments received
by enrolled subjects, the availability of appropriate clinical trial investigators, support staff, and proximity of patients to clinical sites and able to comply with the eligibility and exclusion criteria for participation in the clinical trial and
patient compliance. For example, patients may be discouraged from enrolling in our clinical trials if the trial protocol requires them to undergo extensive post-treatment procedures or follow-up to assess the safety and effectiveness of our products
or if they determine that the treatments received under the trial protocols are not attractive or involve unacceptable risks or discomforts. Patients may also not participate in our clinical trials if they choose to participate in contemporaneous
clinical trials of competitive products.

Development of sufficient and appropriate clinical protocols to demonstrate safety
and efficacy may be required and we may not adequately develop such protocols to support clearance or approval. Delays in patient enrollment or failure of patients to continue to participate in a clinical trial may cause an increase in costs and
delays in the approval and attempted commercialization of our products or result in the failure of the clinical trial. In addition, despite considerable time and expense invested in our clinical trials, FDA may not consider our data adequate to
demonstrate safety and efficacy. Such increased costs and delays or failures could adversely affect our business, operating results and prospects.

If we fail to comply with healthcare laws and regulations, we could face substantial penalties and our business, operations and financial condition could be adversely affected.

While we do not control referrals of healthcare services or bill directly to Medicare, Medicaid or other third-party payors, due to the
breadth of many healthcare laws and regulations, we cannot assure you that they will not apply to our business. We could be subject to healthcare fraud and patient privacy regulation by both the federal government and the states in which we conduct
our business. The regulations that may affect our ability to operate include:



| |  |  | the federal healthcare program Anti-Kickback Law, which prohibits, among other things, persons from soliciting, receiving or providing remuneration,
directly or indirectly, to induce either the referral of an individual, for an item or service or the purchasing or ordering of a good or service, for which payment may be made under federal healthcare programs such as the Medicare and Medicaid
programs;
| | - |  | -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------



| |  |  | federal false claims laws which prohibit, among other things, individuals or entities from knowingly presenting, or causing to be presented, claims for
payment from Medicare, Medicaid, or other third-party payors that are false or fraudulent, and which may apply to entities like us which provide coding and billing advice to customers or whose products are frequently used off-label;
| | - |  | ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------



| |  |  | the federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, which prohibits executing a scheme to defraud any healthcare benefit
program or making false statements relating to healthcare matters and which also imposes certain requirements relating to the privacy, security and transmission of individually identifiable health information;
| | - |  | -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------



48



---

##### Table of Contents

| |  |  | federal self-referral laws, such as STARK, which prohibit a physician from making a referral to a provider of certain health services with which the
physician or the physicians family member has a financial interest, and prohibits submission of a claim for reimbursement pursuant to a prohibited referral; and
| | - |  | ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------



| |  |  | state law equivalents of each of the above federal laws, such as anti-kickback and false claims laws which may apply to items or services reimbursed by
any third-party payor, including commercial insurers, and state laws governing the privacy of health information in certain circumstances, many of which differ from each other in significant ways and often are not preempted by HIPAA, thus
complicating compliance efforts.
| | - |  | ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

If our operations are found to be in violation of any of the laws
described above or any other governmental regulations that apply to us, we may be subject to penalties, including civil and criminal penalties, damages, fines, exclusion of our products from reimbursement under Medicare and Medicaid programs and the
curtailment or restructuring of our operations. Any penalties, damages, fines, curtailment or restructuring of our operations could adversely affect our ability to operate our business and our financial results. The risk of our being found in
violation of these laws is increased by the fact that many of them have not been fully interpreted by the regulatory authorities or the courts, and their provisions are open to a variety of interpretations. Any action against us for violation of
these laws, even if we successfully defend against it, could cause us to incur significant legal expenses and divert our managements attention from the operation of our business. Moreover, to achieve compliance with applicable federal and
state privacy, security, and electronic transaction laws, we may be required to modify our operations with respect to the handling of patient information. Implementing these modifications may prove costly. At this time, we are not able to determine
the full consequences to us, including the total cost of compliance, of these various federal and state laws.

The
application of state certificate of need regulations and compliance with federal and state licensing requirements could substantially limit our ability to sell our products and grow our business.

Some states require healthcare providers to obtain a certificate of need or similar regulatory approval prior to the acquisition of
high-cost capital items such as our Sensei system. In many cases, a limited number of these certificates are available and, as a result, hospitals and other healthcare providers may be unable to obtain a certificate of need for the purchase of our
Sensei system. Further, our sales cycle for our system is typically longer in certificate of need states due to the time it takes our customers to obtain the required approvals. In addition, our customers must meet various federal and state
regulatory and/or accreditation requirements in order to receive reimbursement from government-sponsored healthcare programs such as Medicare and Medicaid and other third-party payors. Any lapse by our customers in maintaining appropriate licensure,
certification or accreditation, or the failure of our customers to satisfy the other necessary requirements under government-sponsored healthcare programs, could cause our sales to decline.

Risks Related to Ownership of Our Common Stock

The trading price of our common stock has been volatile and is likely to be volatile in the future.

The trading price of our common stock has been highly volatile. Further, our common stock has a limited trading history. Since our initial public offering in November 2006 through April 30, 2009, our
stock price has fluctuated from a low of $2.65 to a high of $39.32. The market price for our common stock may be affected by a number of factors, including:



| |  |  | the announcement of our operating results, including the number of our Sensei systems sold during a period and our resulting revenue for the period,
and the comparison of these results to the expectations of analysts and investors;
| | - |  | ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------



| |  |  | the receipt, denial or timing of regulatory clearances, approvals or actions of our products or competing products;
| | - |  | -------------------------------------------------------------------------------------------------------------------



49



---

##### Table of Contents

| |  |  | changes in policies affecting third-party coverage and reimbursement in the United States and other countries;
| | - |  | --------------------------------------------------------------------------------------------------------------



| |  |  | ability of our products to achieve market success;
| | - |  | --------------------------------------------------



| |  |  | the performance of third-party contract manufacturers and component suppliers;
| | - |  | ------------------------------------------------------------------------------



| |  |  | our ability to develop sales and marketing capabilities;
| | - |  | --------------------------------------------------------



| |  |  | our ability to manufacture our products to meet commercial and regulatory standards;
| | - |  | ------------------------------------------------------------------------------------



| |  |  | our ability to manage costs and improve margins;
| | - |  | ------------------------------------------------



| |  |  | the success of any collaborations we may undertake with other companies;
| | - |  | ------------------------------------------------------------------------



| |  |  | our ability to develop, introduce and market new or enhanced versions of our products on a timely basis;
| | - |  | --------------------------------------------------------------------------------------------------------



| |  |  | actual or anticipated variations in our results of operations or those of our competitors;
| | - |  | ------------------------------------------------------------------------------------------



| |  |  | announcements of new products, technological innovations or product advancements by us or our competitors;
| | - |  | ----------------------------------------------------------------------------------------------------------



| |  |  | announcements of acquisitions or dispositions by us or our competitors;
| | - |  | -----------------------------------------------------------------------



| |  |  | developments with respect to patents and other intellectual property rights;
| | - |  | ----------------------------------------------------------------------------



| |  |  | sales of common stock or other debt or equity securities by us or our stockholders in the future;
| | - |  | -------------------------------------------------------------------------------------------------



| |  |  | additions or departures of key scientific or management personnel;
| | - |  | ------------------------------------------------------------------



| |  |  | disputes or other developments relating to proprietary rights, including patents, litigation matters and our ability to obtain patent protection for
our technologies;
| | - |  | ----------------------------------------------------------------------------------------------------------------------------------------------------------------------



| |  |  | trading volume of our common stock;
| | - |  | -----------------------------------



| |  |  | our announcements of guidance regarding future operating or financial results which fails to meet investor or analyst expectations or which differs
from our previously-announced guidance;
| | - |  | -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------



| |  |  | changes in earnings estimates or recommendations by securities analysts, failure to obtain analyst coverage of our common stock or our failure to
achieve analyst earnings estimates;
| | - |  | -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------



| |  |  | public statements by analysts or clinicians regarding their perceptions of the effectiveness of our products;
| | - |  | -------------------------------------------------------------------------------------------------------------



| |  |  | developments in our industry; and
| | - |  | ---------------------------------



| |  |  | general market conditions and other factors unrelated to our operating performance or the operating performance of our competitors.
| | - |  | -----------------------------------------------------------------------------------------------------------------------------------

The stock prices of many companies in the medical device industry have experienced wide fluctuations that
have often been unrelated to the operating performance of these companies. Following periods of volatility in the market price of a companys securities, stockholders have often instituted class action securities litigation against those
companies. Class action securities litigation, if instituted against us, could result in substantial costs and a diversion of our management resources, which could significantly harm our business.

Securities analysts may not continue, or additional securities analysts may not initiate, coverage for our common stock or may issue
negative reports, and this may have a negative impact on the market price of our common stock.

Currently, several
securities analysts provide research coverage of our common stock. Several analysts have already published statements that do not portray our technology, products or procedures using our products in a positive light and others may do so in the
future. If we are unable to educate those who



50



---

##### Table of Contents

publicize such reports about the benefits we believe our technology provides, or if one or more of the analysts who elects to cover us downgrades our stock, our stock price would likely decline
rapidly. If one or more of these analysts ceases coverage of our company, we could lose visibility in the market, which in turn could cause our stock price to decline. The trading market for our common stock may be affected in part by the research
and reports that industry or financial analysts publish about us or our business. If sufficient securities analysts do not cover our common stock, the lack of research coverage may adversely affect the market price of our common stock. It may be
difficult for companies such as ours, with smaller market capitalizations, to attract and maintain sufficient independent financial analysts that will cover our common stock. This could have a negative effect on the market price of our stock.

Our principal stockholders, directors and management own a large percentage of our voting stock, which allows them to
exercise significant influence over matters subject to stockholder approval.

Our executive officers, directors and
stockholders holding 5 percent or more of our outstanding common stock beneficially own or control approximately 33.5 percent of the outstanding shares of our common stock as of April 21, 2009. Accordingly, these executive officers, directors
and principal stockholders, acting as a group, have substantial influence over the outcome of corporate actions requiring stockholder approval, including the election of directors, any merger, consolidation or sale of all or substantially all of our
assets or any other significant corporate transaction. These stockholders may also delay or prevent a change of control or otherwise discourage a potential acquirer from attempting to obtain control of us, even if such a change of control would
benefit our other stockholders. This significant concentration of stock ownership may adversely affect the trading price of our common stock due to investors perception that conflicts of interest may exist or arise.

We have not paid dividends in the past and do not expect to pay dividends in the future, and any return on investment may be limited
to the value of our common stock.

We have never paid dividends on our common stock and do not anticipate paying
dividends on our common stock in the foreseeable future. The payment of dividends on our common stock will depend on our earnings, financial condition and other business and economic factors affecting us at such time as our board of directors may
consider relevant. If we do not pay dividends, our common stock may be less valuable because a return on your investment will only occur if our stock price appreciates. Pursuant to our agreement with Silicon Valley Bank, we must obtain Silicon
Valley Banks prior written consent in order to pay any dividends on our common stock.

Some provisions of our
charter documents and Delaware law may have anti-takeover effects that could discourage an acquisition of us by others, even if an acquisition would be beneficial to our stockholders.

Provisions in our amended and restated certificate of incorporation and amended and restated bylaws, as well as provisions of Delaware law,
could make it more difficult for a third party to acquire us, even if doing so would benefit our stockholders. These provisions:



| |  |  | permit our board of directors to issue up to 10,000,000 shares of preferred stock, with any rights, preferences and privileges as they may designate,
including the right to approve an acquisition or other change in our control;
| | - |  | -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------



| |  |  | provide that the authorized number of directors may be changed only by resolution of the board of directors;
| | - |  | ------------------------------------------------------------------------------------------------------------



| |  |  | provide that all vacancies, including newly created directorships, may, except as otherwise required by law, be filled by the affirmative vote of a
majority of directors then in office, even if less than a quorum;
| | - |  | ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------



| |  |  | divide our board of directors into three classes;
| | - |  | -------------------------------------------------



| |  |  | require that any action to be taken by our stockholders must be effected at a duly called annual or special meeting of stockholders and not be taken by
written consent;
| | - |  | ------------------------------------------------------------------------------------------------------------------------------------------------------------------------



51



---

##### Table of Contents

| |  |  | provide that stockholders seeking to present proposals before a meeting of stockholders or to nominate candidates for election as directors at a
meeting of stockholders must provide notice in writing in a timely manner, and also specify requirements as to the form and content of a stockholders notice;
| | - |  | ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------



| |  |  | do not provide for cumulative voting rights, therefore allowing the holders of a majority of the shares of common stock entitled to vote in any
election of directors to elect all of the directors standing for election, if they should so choose;
| | - |  | ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------



| |  |  | provide that special meetings of our stockholders may be called only by the chairman of the board, our chief executive officer or by the board of
directors pursuant to a resolution adopted by a majority of the total number of authorized directors; and
| | - |  | -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------



| |  |  | provide that stockholders will be permitted to amend our amended and restated bylaws only upon receiving at least 662/3percent of the votes entitled to be cast by holders of all
outstanding shares then entitled to vote generally in the election of directors, voting together as a single class.
| | - |  | -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

In addition, we are subject to Section 203 of the Delaware General Corporation Law, which generally prohibits a Delaware corporation from engaging in any broad range of business combinations with any
stockholder who owns, or at any time in the last three years owned, 15 percent or more of our outstanding voting stock for a period of three years following the date on which the stockholder became an interested stockholder. This provision could
have the effect of delaying or preventing a change of control, whether or not it is desired by or beneficial to our stockholders.

Future sales of a substantial number of shares of our common stock in the public market, the announcement to undertake such sales, or the perception that they may occur, may depress the market price of our common stock.

Sales of substantial amounts of our common stock by us or by our stockholders, announcements of the proposed sales of
substantial amounts of our common stock or the perception that substantial sales may be made, could cause the market price of our common stock to decline. We may issue additional shares of our common stock in follow-on offerings to raise additional
capital or in connection with acquisitions or corporate alliances and we plan to issue additional shares to our employees, directors or consultants in connection with their services to us. All of the currently outstanding shares of our common stock
are freely tradable under federal and state securities laws, except for shares held by our directors, officers and certain greater than 5 percent stockholders, which may be subject to volume limitations. Due to these factors, sales of a substantial
number of shares of our common stock in the public market could occur at any time. Such sales could reduce the market price of our common stock.

Our financial results may vary significantly from period to period, which may reduce our stock price.

Our financial results may fluctuate as a result of a number of factors, many of which are outside of our control, which may cause the market price of our common stock to fall. For these reasons, comparing
our operating results on a period-to-period basis may not be meaningful, and you should not rely on our past results as an indication of our future performance. Our financial results may be negatively affected by any of the risk factors listed in
this Risk Factors section.

We incur significant costs as a result of operating as a public company, and our
management is required to devote substantial time to new compliance initiatives.

As a public company, we incur
significant legal, accounting and other expenses that we did not incur as a private company. In addition, the Sarbanes-Oxley Act, as well as rules subsequently implemented by the United States Securities and Exchange Commission and the Nasdaq Global
Market, have imposed various new requirements on public companies, including requiring establishment and maintenance of effective disclosure and financial controls and changes in corporate governance practices. Our management and other personnel
devote a substantial amount of time to these requirements. Moreover, these rules and



52



---

##### Table of Contents

regulations increase our legal and financial compliance costs and make some activities more time-consuming and costly. For example, we expect these rules and regulations to make it more difficult
and more expensive for us to obtain director and officer liability insurance, and we may be required to incur substantial costs to maintain the same or similar coverage.

The Sarbanes-Oxley Act of 2002, or Sarbanes-Oxley Act, requires, among other things, that we maintain effective internal controls for financial reporting and disclosure controls and procedures. In
particular, commencing in fiscal 2007, we were required to perform a system and process evaluation and testing of our internal controls over financial reporting to allow management and our independent registered public accounting firm to report on
the effectiveness of our internal controls over financial reporting, as required by Section 404 of the Sarbanes-Oxley Act. As a result of our compliance with Section 404, we have incurred and will continue to incur substantial accounting
expense and expend significant management efforts and we may need to hire additional accounting and financial staff with appropriate public company experience and technical accounting knowledge to ensure continuing compliance.

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

(a) Sales of Unregistered Securities

Not applicable.

(b) Uses of Proceeds from Sale of Registered Securities

Not applicable.

(c) Purchases of Equity Securities

None.

ITEM 3. DEFAULTS UPON SENIOR SECURITIES

None.

ITEM 4. SUBMISSION OF MATTERS TO A VOTE OF SECURITY
HOLDERS

None.

ITEM 5. OTHER INFORMATION

None.



53



---

##### Table of Contents

ITEM 6. EXHIBITS

Exhibits



|              |  |                                                                                                                                       
|------------- |  | --------------------------------------------------------------------------------------------------------------------------------------
|ExhibitNumber |  | Description                                                                                                                           
|3.1(1)        |  | Amended and Restated Certificate of Incorporation of the Registrant.                                                                  
|              | 
|3.2(2)        |  | Amended and Restated Bylaws of the Registrant.                                                                                        
|              | 
|4.1(3)        |  | Specimen Common Stock Certificate.                                                                                                    
|              | 
|4.2(3)        |  | Amended and Restated Investor Rights Agreement, dated November 10, 2005, between the Registrant and certain of its stockholders.      
|              | 
|10.40         |  | Letter from Christopher P. Lowe, dated March 19, 2009 regarding reduction of cash fees for non-employee director services during 2009.
|              | 
|10.41         |  | Letter from Thomas C. McConnell, dated March 19, 2009 regarding waiver of cash fees for non-employee director services during 2009.   
|              | 
|10.42         |  | Letter from James M. Shapiro, dated March 19, 2009 regarding waiver of cash fees for non-employee director services during 2009.      
|              | 
|10.43         |  | Letter from Russell C. Hirsch, dated March 24, 2009 regarding waiver of cash fees for non-employee director services during 2009.     
|              | 
|31.1          |  | Certification of the Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.                               
|              | 
|31.2          |  | Certification of the Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.                               
|              | 
|32.1*         |  | Certification of the Chief Executive Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.                               
|              | 
|32.2*         |  | Certification of the Chief Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.                               



|(1) | Previously filed as an exhibit to Registrants Annual Report on Form 10-K, filed on March 28, 2007 and incorporated herein by reference.
|--- | ----------------------------------------------------------------------------------------------------------------------------------------

|(2) | Previously filed as an exhibit to Registrants Current Report on Form 8-K, filed on February 16, 2007 and incorporated herein by reference.
|--- | -------------------------------------------------------------------------------------------------------------------------------------------

|(3) | Previously filed as an exhibit to Registrants Registration Statement on Form S-1, as amended, originally filed on August 16, 2006 and incorporated herein by
reference.
|--- | ------------------------------------------------------------------------------------------------------------------------------------------------------------------------

|* | The certifications attached hereto as Exhibits 32.1 and 32.2 accompany this Quarterly Report on Form 10-Q/A are not deemed filed with the Securities and Exchange
Commission and are not to be incorporated by reference into any filing of Hansen Medical, Inc. under the Securities Act of 1933, as amended, or the Exchange Act (whether made before or after the date of this Form 10-Q/A), irrespective of any general
incorporation language contained in such filing.
|- | ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------



54



---

##### Table of Contents

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorized.



|                         |  |  |  |     |  |                                                                                        
|------------------------ |  |  |  | --- |  | ---------------------------------------------------------------------------------------
|                         |  |  | 
|Dated: November 16, 2009 |  |  |  | By: |  | /s/    FREDERIC H. MOLL,
M.D.                                                          
|                         |  |  |  |     |  | Frederic H. Moll, M.D. Chief Executive Officer (Principal Executive
Officer)           
|                         |  |  | 
|Dated: November 16, 2009 |  |  |  | By: |  | /s/    STEVEN M. VAN
DICK                                                              
|                         |  |  |  |     |  | Steven M. Van Dick Chief Financial Officer (Principal Financial and Accounting Officer)



55